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The synthesis of a mixture of epimeric derivatives of the peptaibol Trichotoxin A-50 
(G) is described. The ‘azirine/oxazolone method’ has been used as a superior method for the 
introduction of the Aib as well as the Iva units into the peptide chain. In this protocol, 2,2-
disubstituted 2H-azirin-3-amines are the synthons for 2,2-disubstituted glycines, which 
undergo the coupling with N-protected amino or peptide acids in high yield and without any 
need of coupling reagents. The problem of the instability of the amide function of the Gln side 
chain under the conditions of the acid catalyzed hydrolysis of Z-Gln-(Aib)n-N(Me)Ph has 
been solved by using an appropriate protecting group for the amide function of the Gln side 
chain, e.g., the triphenylmethyl (trityl) group. The structures of two intermediate peptides, i.e., 
segment (1–5) and segment (10–13), have been establisheded by X-ray crystallography. 
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1. Introduction. – Peptaibols are linear, amphiphilic polypeptides of fungal origin 
with 11–20 amino acids [1]. In addition to proteinogenic amino acids, they contain up to 50% 
2-aminoisobutyric acid (Aib) [2] and sometimes isovaline (Iva, 2-amino-2-methylbutyric 
acid) [3][4]. These α,α-disubstituted amino acids (2,2-disubstituted glycines) are well known 
for their ability to induce helical folding of the peptide chain [5–7].  This effect still 
dominates when amino acids such as proline (Pro) or hydroxyproline (Hyp), which often are 
called ‘helix-breakers’, are present [8]. Therefore, peptaibols exhibit an overall helical 
structure. Further characteristics are the acetylated N-terminus and the presence of an α-
amino alcohol such as valinol (Valol), leucinol (Leuol) or phenylalaninol (Pheol) as the C-
terminus [9][10]. Peptaibols are ‘membrane-active’ polypeptide antibiotics, which, after 
aggregation to bundles, form ‘ion-channels’ through biological membranes [11][12]. 
A well-known class of the peptaibols is the Trichotoxin family, which was isolated 
from the mycel of the fungus Trichoderma viride NRRL 5242 [13]. The Trichotoxin A-50 
mixture (Tab. 1) was obtained after ‘counter-current distribution’ (CCD) [13a][14], the 
components were separated by HPLC, and their sequences could be determined by means of 
FAB- and FD-MS [15]. Recent work was devoted to the mechanism of formation of 
Trichotoxin channels in which the presence of octameric or hexameric bundles was proposed 
[16][17]. 
 
Table 1. Sequences of Trichotoxins A-50 [15] 
 
Another challenge is the synthesis of peptaibols as analytically pure compounds, 
which can be used for the investigation of structure-activity relationships (SAR) with respect 
to bactericide and fungicide properties [18]. The introduction of Aib into a peptide chain had 
been a difficult task [19], but these difficulties have been surmounted by the development of 
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highly reactive coupling reagents and activated amino acids [20][21]. For example, several 
segments of members of the Trichotoxin A-50 family have been synthesized, and X-ray 
crystal-structure determinations of Z-Aib-Gly-Aib-Leu-Aib-OtBu [22a], Z-Aib-Aib-Aib-Ala-
Ala-Aib-OtBu [22b], Z-Aib-Gly-Aib-OH [22c], and Ac-Aib-Gly-Aib-OH [22c] were carried 
out. 
The total synthesis of Trichotoxin A-50 (E) was reported by Brückner on the occasion 
of the ‘19th European Peptide Symposium’ [23]. They used the Z/OtBu strategy and the water-
soluble N-ethyl-N-[3-(dimethylamino)propyl]carbodiimide (EDC) as the coupling reagent. 
The preparation of the segment Z-Leu-Aib-Gln-Aib-Aib-Aib-Ala-OtBu (segment 4–10) was 
mentioned as being difficult, but the coupling reactions of the main segments to give the 
octadecapeptide occurred in very good yield (Scheme 1). 
 
Scheme 1 
 
Almost 20 years ago, we elaborated a different method for the introduction of hindered 
2,2-disubstituted glycines into peptide chains, i.e., the ‘azirine/oxazolone method’ [24] (and 
refs. cited therein). The key reaction steps are the reaction of an amino or peptide acid 1 with 
a 2,2-disubstituted 2H-azirin-3-amine 2 to yield the extended peptide 3 (Scheme 2). Selective 
hydrolysis of the C-terminal N,N-disubstituted amide bond leads to the extended peptide acid 
4, which can be coupled with a second azirine 2 to give 5 [25]. Alternatively, 4 can be used in 
conventional coupling reactions with an amino component, e.g. 7, to give peptide 8. The 
activated acid derivative is the intermediate 5(4H)-oxazolone 6, which is easily formed 
because of the disubstitution at C(2) of the C-terminal amino acid in 4 (Thorpe-Ingold or 
gem-dialkyl effect [26]). The formation of the same oxazolone 6 is responsible for the 
selectivity of the hydrolysis of 3 to give 4 [25d]. 
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Scheme 2 
 
The use of the ‘azirine/oxazolone method’ has been demonstrated by its application to 
the synthesis of peptaibols or segments thereof, e.g., the C-terminal nonapeptide of 
Alamethicin F30 [27], segment (14–18) of Trichotoxin A50 [28], a derivative of Trichovirin I 
1B [29], segment (6–16) of Zervamicin II-2 [30], and Hypomurocin A1 [31]. 
Very recently, the ‘azirine/oxazolone method’ has been adapted to solid phase peptide 
synthesis [32]. This method was applied successfully to the preparation of a derivative of 
Trichovirin I 1B [32c]. 
In the present paper, we describe the synthesis of a mixture of epimeric derivatives of 
the peptaibol antibiotic Trichotoxin A-50 (G) (9) by using the ‘azirine/oxazolone method’2). 
 
2. Results and Discussion. – An overview of the synthesis of 9 is shown in Scheme 3. 
The peptaibol was built up from the main segments Z-Aib-Gly-Aib-Leu-Aib-OH (10, 
segment (1–5)), Z-Gln(Trt)-Aib-Aib-Aib-OH (11a, segment (6–9)), H-Ala-Ala-Aib-Pro-OtBu 
(12, segment (10–13)), and H-Leu-Aib-Iva-Gln-Valol (13, segment (14–18)) by using DCC, 
HOBt, and CSA or TBTU, HOBt3) as the coupling reagents. Our intention was to use the 
‘azirine/oxazolone method’ for the introduction of the Aib units in positions 3,5,7,8,9,12, and 
15 as well as Iva in position 16. The building blocks for the two amino acids were the 2H-
azirin-3-amines 2a [34] and 2b [35].  
 
                                                          
2) For a preliminary communication, see [33]. 
3) Abbreviations: N,N’-dicyclohexylcarbodiimid (DCC); 1-hydroxybenzotriazole (HOBt); 
camphor-10-sulfonic acid (CSA); O-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate (TBTU);  triphenylmethyl (Trt); N-methylmorpholine (NMM). 
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Scheme 3, Formulae 2a and 2b 
 
2.1. Synthesis of Z-Aib-Gly-Aib-Leu-Aib-OH (10). – The preparation of segment (1–5) 
was carried out according to the general concept depicted in Scheme 2. Coupling of Z-Gly-
OH with the Aib-synthon 2a to give 14 and subsequent hydrolysis of the terminal amide 
group gave dipeptide 15 in 89% yield (Scheme 4). In an analogous manner, dipeptide 16 was 
synthesized from Z-Leu-OH and 2a; hydrogenolysis led to the N-deprotected 17 in 93% yield. 
Treatment of a mixture of 15 and 17 with DCC, HOBt, and ZnCl2 [25b] yielded the 
corresponding tetrapeptide, which was deprotected at the N-terminus to give 18 (79%). The 
coupling with Z-Aib-OH and subsequent selective hydrolysis gave the pentapeptide 10 in 
76% yield. The analogous preparation of Ac-Aib-Gly-Aib-Leu-Aib-OH from 18 and Ac-Aib-
OH proved to be less satisfactory as the product was obtained in only 12% yield. The main 
difficulty is the lability of the Ac-Aib terminus under the acidic conditions of the hydrolysis4). 
 
Scheme 4 
 
The conformation of 10 in the solid state was established by X-ray crystallography 
(Fig. 1). The relevant torsion angles φ and ψ and the H-bonding parameters are collected in 
Table 2. The OH and all NH groups of the molecule act as H-bond donors, while each of the 
carbonyl O-atoms acts as single H-bond acceptor. The OH group, plus N(4)–H and N(5)–H 
form intramolecular H-bonds with carbonyl O-atoms that are, unusually, not always the same 
number of atoms further along the peptide backbone. These three interactions form loops that 
can be described by graph set motifs [38] of S(16), S(13), and S(10), respectively. Two of the 
                                                          
4) This assumption has been proven by a series of control experiments with different N-
acylated derivatives of 2,2-disubsituted glycines [36]. 
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intermolecular interactions link the molecules into extended chains which run parallel to the 
[010] direction and each interaction can be described by a graph set motif of C(11). The third 
intermolecular interaction links the molecules into extended chains which run parallel to the 
[100] direction and can also be described by a graph set motif of C(11). The combination of 
both interactions links the molecules into two-dimensional networks, which lie parallel to 
(001). 
 
Fig. 1. ORTEP-Plot [37] of the molecular structure of 10 (arbitrary numbering of 
atoms, 50% probability ellipsoids, H-atoms bonded to C-atoms have been omitted for clarity) 
 
Table 2. Torsion Angles and H-Bonding Parameters in the Crystal-Structure of 10  
 
The torsion angles of Aib(1), Gly(2), and Aib(3) as well as the intramolecular H-bond 
N(4)–H…O(2) between NH of Leu(4) and the urethane C=O are in accordance with a right-
handed α-helical structure, whereas the torsion angles of Aib(5) correspond with a left-
handed α-helix (see Table 2). A similar conformation for Z-Aib-Gly-Aib-Leu-Aib-OtBu has 
been described by Gessmann et al. [22a]. 
 
2.2. Synthesis of Z-Gln-Aib-Aib-Aib-Ala-Ala-Aib-Pro-OH (19). – The octapeptide 19 
(segment (6–13)) was built up by condensation of the two tetrapeptides 11a and 12, i.e., 
segments (6–9) and (10–13). The latter was prepared by the reaction of Z-Ala-Ala-OH with 
the Aib-synthon 2a, subsequent selective hydrolysis of the terminal amide group to give 20, 
coupling with H-Pro-OtBu by using DCC and catalytic amounts of CSA to yield 21, and 
8 
 
finally deprotection of the amino group (Scheme 5). The total yield over all four reactions was 
80.3%5). 
 
Scheme 5 
 
The crystal-structure of 21 was also determined by X-ray crystallography (Fig. 2). The 
central amide group of the molecule does not partake in any H-bonds. Each of the other two 
amide groups forms an intermolecular H-bond with an amide O-atom of a neighboring 
molecule. The interaction involving N(1)–H links the molecules into extended chains which 
run parallel to the [010] direction and can be described by the graph set motif [38] of C(5). 
The interaction involving N(3)–H also links the molecules into extended chains with the C(5) 
motif and which also run parallel to the [010] direction. The combination of both interactions 
links the molecules into two-dimensional networks, which lie parallel to (100). There are no 
‘cross-chain’ H-bonds, which are typical for helical peptide conformations. The torsion angles 
of Ala(1) are close to those of a 310-helical structure, and φ and ψ of Aib(3) are almost ideal 
for a left-handed α-helix. On the other hand, the torsion angles of Ala(2) correspond with 
those of an antiparallel β-sheet (see e.g. [40]). 
 
Fig. 2. ORTEP-Plot [37] of the molecular structure of 21 (arbitrary numbering of 
atoms, 30% probability ellipsoids, H-atoms bonded to C-atoms have been omitted for clarity) 
                                                          
5) In the meantime we have shown that the direct introduction of the Aib-Pro sequence by 
azirine coupling with the dipeptide synthon 22 is a highly recommendable method [29–
31][32c][39]. 
 
Formula 22 
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Table 3. Torsion Angles and H-Bonding Parameters in the Crystal-Structure of 21  
 
The ‘azirine/oxazolone method’ is ideally suited for the synthesis of poly-Aib peptides 
[25c][41–43]. Therefore, the plan was to carry out the preparation of the tetrapeptide 11a 
straightforwardly by repeated coupling of Z-Gln-OH with azirine 2a and hydrolysis. A large 
series of preliminary experiments in connection with the syntheses of Z-Asn-Xaa-Xbb-OH 
(Xaa or Xbb = 2,2-disubstituted glycines) and the corresponding Gln derivatives showed that 
under the conditions of the hydrolysis of the terminal N-methyl-N-phenyl amide (see Scheme 
2), the side-chain amide function of Asn and Gln was also hydrolyzed partially [36]. 
Therefore, a suitably protected Gln derivative had to be used. In control experiments, it was 
demonstrated that the bis(2,4-dimethoxybenzyl) (DMB)2 [44], the 4,4’-dimethoxybenzhydryl 
(4,4’dimethoxydityl, Dod) [45], and the triphenylmethyl (trityl, Trt) [46][47] group are 
appropriate protecting groups, as they are relatively stable in 3N HCl as well as during 
catalytic hydrogenation, but can be removed by treatment with CF3COOH (TFA) [36]6)7). 
The results of this study are collected in Table 4. The repeated coupling of the Aib-synthon 2a 
with Z-Gln(X) derivatives 23a–23c, as well as the selective hydrolysis of the Aib-containing 
                                                          
6) In the case of the DMB and Dod groups, addition of anisol is recommended, which 
intercepts the generated cation and, therefore, accelerates the reaction [45]. 
7) The deprotection of the dipeptides Z-Gln(X)-Aib-OMe by using the described conditions, 
i.e., TFA at room temperature in the case of X = Trt, and TFA and 5–10% anisole at room 
temperature for X = (DMB)2 and Dod, gave Z-Gln-Aib-OMe in 91, 64, and 75% yield, 
respectively [36]. 
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peptide amides, occurred under mild conditions and with high yield; the total yield of the 
tetrapeptide acids 11a, 11b, and 11c reach 62, 64, and 73%, respectively8). 
 
Table 4. Yields of the Coupling of Azirine 2a and the Hydrolysis of the Terminal 
Amide Group of Z-Gln(X)-(Aib)n-N(Me)Ph Derivatives 
 
The two tetrapeptide segments 11a and 12 were coupled with DCC, HOBt, and CSA 
in DMF; the fully protected octapeptide 24 was obtained in 97% yield (Scheme 6). Selective 
deprotection of the N-terminus to give 25 was achieved by hydrogenolysis, and treatment of 
24 with TFA at 0° removed the protecting groups of the C-terminus and of the Gln side chain 
simultaneously to yield 19. The structures of the products were established on the basis of 
their 1H- and 13C-NMR and mass spectra. For example, the ESI- and FAB-MS of 19 are 
shown in Fig. 3. 
 
Scheme 6 
 
Fig. 3. Mass-Spectra of the Octapeptide 19; a) ESI-MS and b) FAB-MS 
 
                                                          
8) The deprotection of the NH2 group by hydrogenation (H2, Pd/C) of the various derivatives 
listed in Table 4 was achieved in 74-100% yield [36]. Furthermore, the transformation of 
some examples of Z-Gln(X)-(Aib)n-N(Me)Ph (Table 4) into the corresponding methyl esters 
by treatment with HCl gas in MeOH was carried out at 25–65°, which led to the product in 
70–96% yield [36]. 
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2.3. Synthesis of H-Leu-Aib-D,L-Iva-Gln-Valol (13). – This segment was prepared as a 
mixture of the D- and L-Iva epimers (Scheme 7). Subsequent coupling of Z-Leu-OH with the 
Aib and Iva synthons 2a and 2b under standard conditions gave tripeptide 27, which was then 
coupled with the terminal dipeptide 28 by using TBTU/HOBt as the coupling reagent. 
 
Scheme 7 
 
In preliminary studies, it has been shown that the two diastereoisomers of 27 can be 
separated by means of prep. HPLC (Nucleosil 100-7, hexane/CH2Cl2/EtOH), but only ca. 
10% of the (+)-epimer could be isolated in pure form. The second epimer was obtained as a 
ca. 1:8 mixture of both isomers9)10). 
 
                                                          
9) For this reason, we have prepared 2H-azirin-3-amines 2c–2f, which could be used as 
synthons for enantiomerically pure Iva. Whereas the diastereoisomers of 2c [36] and 2d [48] 
could not be separated on a preparative scale, the optically pure diastereoisomers of 2e and 2f 
were obtained after chromatographic separation (CC). Furthermore, it has been shown that 
they are suitable for use in the ‘azirine/oxazolone method’ [49][50]. For example, the two 
epimers Z-Leu-Aib-D-Iva-Gln-Valol and Z-Leu-Aib-L-Iva-Gln-Valol have been synthesized 
[49][51]. 
 
Formulae 2c–2f 
 
10) Brückner et al. showed by means of GC methods that the two Iva units of the peptaibol 
‘Antiamoebin I’ have the (R)-configuration (i.e., D-Iva) [52] (for the crystal structure of Ac-
Aib-Aib-D-Iva-OMe.H2O, see [53]). 
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2.4. Coupling of the Segments 10, 19, and 13. – The synthesis of the Trichotoxin A-50 
(G) derivative 9 was achieved – although in only moderate yield – by coupling of the 
segments (1–5), (6–13), and (14–18) under standard conditions (Scheme 8). First, the C-
deprotected octapeptide 19 and the C-terminal pentapeptide 13 (as a mixture of two epimers) 
were treated with DCC, HOBt, and CSA to give the crystalline peptide 29 as a mixture of two 
diastereoisomers in 39% yield. The analogous condensation with TBTU/HOBt was less 
satisfactory and gave the same product 29 in only 28% yield. Deprotection of 29 by 
hydrogenolysis and subsequent coupling with the N-terminal pentapeptide 10 by using 
TBTU/HOBt yielded the final product 9 as a mixture of two epimers (37%). The structure of 
the latter was confirmed by its ESI-MS. 
 
Scheme 8 
 
As an alternative approach, the N-terminal pentapeptide 10 was coupled with the N-
deprotected octapeptide 25 by using the TBTU/HOBt methodology to give the protected 
tridecapeptide Z-Aib-Gly-Aib-Leu-Aib-Gln(Trt)-(Aib)3-Ala-Ala-Aib-Pro-OtBu (30) in 51% 
yield. Simultaneous deprotection of the C-terminus and the side chain of Gln was achieved in 
TFA at 0° in quantitative yield. The resulting segment Z-Aib-Gly-Aib-Leu-Aib-Gln-(Aib)3-
Ala-Ala-Aib-Pro-OH (31) was characterized by ESI and FAB-MS (Fig. 4) and  1H-NMR 
spectroscopy. In the ESI-MS, a minor peak at m/z 1211 indicates the presence of small 
amounts of Z-Aib-Gly-Aib-Leu-Aib-Gln-(Aib)3-Ala-Ala-Aib-OH, which have been formed 
by the treatment with TFA, i.e., the acid labile Aib-Pro bond was not perfectly stable under 
these conditions11). 
 
                                                          
11) The coupling with the C-terminal pentapeptide 13 to give 9 has not been carried out. 
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Fig. 4. Mass-Spectra of the Tridecapeptides 30 and 31; a) ESI-MS of 30, b) ESI-MS of 
31, and c) FAB-MS of 31 
 
3. Conclusion. – The presented synthesis of a derivative of the peptaibol Trichotoxin 
A-50 (G) shows that the ‘azirine/oxazolone method’ is an attractive alternative for the 
preparation of Aib-containing peptides, e.g., naturally occurring peptaibols and non-natural 
analogues. The introduction of Aib, Iva, and other 2,2-disubstituted glycines via the coupling 
reaction of N-protected amino or peptide acids with 2H-azirin-3-amines and subsequent 
selective hydrolysis are very convenient and efficient reactions. Most likely, the modest yields 
of the segment couplings in the presented synthesis can be improved significantly by using a 
different disconnection of the peptaibol, as shown in the synthesis of Trichotoxin A-50 (E) by 
Brückner [23]. 
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Experimental part 
 
1. General. See [31][43a]. The starting materials 2,2-dimethyl-2H-azirin-3-amine (2a) 
and 2-ethyl-2-methyl-2H-azirin-3-amine (2b) were prepared according to [34c][35] from 2,N-
dimethyl-N-phenylpropanamide and 2,N-dimethyl-N-phenylbutanamide by treatment with 
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COCl2 and NaN3 in 72 and 63% yields, respectively. The amino alcohol Valol was prepared 
by reduction of methyl L-valinate hydrochloride with LiAlH4 (83%, [α]D = +16.2 (c = 0.370, 
EtOH) [35]. Amino acids were purchased by Novabiochem and Bachem and are all L-
configured, other reagents and solvents by Aldrich, Fluka and Merck. M.p. were measured on 
a Mettler-FP-5 apparatus, uncorrected. [α]D-Values were determined at 21–23° on a Zeiss-
LEP-A2 polarimeter. IR Spectra were recorded on a Perkin-Elmer-781 spectrometer, in KBr. 
1H-NMR and 13C-NMR spectra were recorded on a Bruker AC-300, Bruker AM-400, and 
Bruker AMX-600 spectrometer at 300, 400, and 600 (1H) and 75.5, 100.8, and 151.2 MHz 
(13C), respectively, in CD3OD if not otherwise stated. ESI-MS were measured on a Finnigan 
TSQ-700 instrument, FAB-MS on a Finnigan MAT-90, and CI-MS (with NH3 or isobutane) 
on a Finnigan MAT-90 or SSQ-700 instrument. Abbreviations. Aib: 2-aminoisobutyric acid 
(2-methylalanin); CME-CDI: N-cyclohexyl-N’-[2-(4-methylmorpholin-4-ylium)ethyl]carbo-
diimide 4-toluolsulfonate; CSA: camphor-10-sulfonic acid; DCC: N,N’-
dicyclohexylcarbodiimide; DIEA: (ethyl)(diisopropyl)amine; HOBt: 1-hydroxybenzotriazole; 
NMM: N-methylmorpholine; OtBu: tert-butyloxy; TBTU: O-(1H-benzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium tetrafluoroborate; TEA: triethylamine; TFA: trifluoroacetic 
acid; Trt: triphenylmethyl; Valol, L-valinol ((S)-2-amino-3-methyl-1-butanol); Z: 
(benzyloxy)carbonyl. 
General Procedure A (GP A, Coupling with 2H-Azirin-3-amines). To a soln. of an N-
protected amino acid or N-protected peptide (5 mmol) in abs. CH2Cl2 (30 ml) at 0°, ca. 1.2 
equiv. of the corresponding 2H-azirin-3-amine in THF or CH2Cl2 were added, and the 
mixture was stirred at r.t. for several h (Ar atmosphere). After completion of the reaction, the 
solvent was evaporated and the product was purified by column chromatography (CC), prep. 
layer chromatography (PLC), or crystallization. 
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General Procedure B (GP B, Selective Hydrolysis of Peptide N-Methyl-N-
phenylamides). A soln. of the peptide amide (5 mmol) in 3N HCl (THF/H2O (1:1), 50 ml) was 
stirred at r.t. for 1–40 h. Then, aq. 2N HCl was added, and the mixture was extracted with 
CH2Cl2 (3x). The org. layers were combined, dried (Na2SO4), and evaporated. The product 
was purified by crystallization. 
General Procedure C (GP C, Hydrogenolytic Deprotection). The N-protected peptide 
(Z-peptide) was dissolved in MeOH, and 10% Pd/C was added to the soln. The mixture was 
stirred at r.t. under an H2 atmosphere overnight. After completion of the reaction (TLC), the 
soln. was filtered through a Celite pad and the solvent was evaporated. The product was dried 
in high vacuum (i.v.).  
General Procedure D (GP D, Peptide Coupling). To a soln. of an N-protected amino 
acid or N-protected peptide in DMF at 0°, 1 equiv. of DCC, 1.1 equiv. of HOBt, ca. 0.1 equiv. 
of CSA or 2 equiv. of ZnCl2, and 1.1 equiv. of a C-protected amino acid or C-protected 
peptide were added. The mixture was stirred overnight at r.t. (N2 atmosphere), N,N'-
dicyclohexylurea was removed by filtration through a Celite pad, and DMF was evaporated. 
The residue was dissolved in CH2Cl2, washed with 2N HCl (2x) and 2N NaOH soln., and 
dried (Na2SO4). The solvent was evaporated and the product was purified by CC or PLC. 
General Procedure E (GP E, Deprotection with TFA). The N-protected peptide was 
dissolved in TFA and the soln. was stirred at 0°–r.t. for 1–8 h. Then, the TFA was evaporated, 
CH2Cl2 was added to the residue, and the procedure was repeated. The crude product was 
purified by CC or PLC or by crystallization after addition of Et2O or hexane.  
2. Preparation of the Pentapeptide Z-Aib-Gly-Aib-Leu-Aib-OH (10). 2.1. Z-Gly-Aib-
OH (15). See [43a]. 
2.2. Z-Leu-Aib-N(Me)Ph (16). According to GP A, Z-Leu-OH (3.03 g, 11.42 mmol) in 
Et2O (50 ml) was treated with 2a (2.20 g, 12.63 mmol) for 13 h: 4.99 g (99%) of 16. Colorless 
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crystals. M.p. 135.5–135.7° (Et2O/pentane). [α]D = –19.6 (c = 1.01, EtOH). IR (CHCl3): 
3430w, 3350w, 3070w, 3010m, 2960m, 1715m, 1680m, 1635m, 1595m, 1510s, 1495s, 1420m, 
1405m, 1390m, 1370m, 1240m, 1170m, 1120m, 1055m, 1030s, 705m. 1H-NMR (CD3OD): 
7.56–7.13 (m, 10 arom. H); 5.15, 5.06 (AB, J = 12.5, PhCH2O); 4.10–3.90 (m, CH(2)(Leu)); 
3.20 (s, MeN); 1.80–1.30 (m, CH2(3)(Leu), CH(4)(Leu)); 1.43 (s, Me2C); 0.92, 0.90 (2d, J = 
6.4, 2 Me(Leu)). 13C-NMR (CD3OD): 175.0, 174.1 (2s, 2 CO(amide)); 158.1 (s, 
CO(urethane)); 146.2, 138.1 (2s, 2 arom. C); 130.4, 130.0, 129.5, 129.3, 129.2, 129.0, 128.8, 
128.6, 128.5, 128.3 (10d, 10 arom. CH); 67.6 (t, PhCH2O); 58.3 (s, Me2C); 54.5 (d, 
C(2)(Leu)); 42.5 (t, C(3)(Leu)); 41.3 (q, MeN); 26.9, 25.8 (2q, Me2C); 26.6 (d, C(4)(Leu)); 
23.6, 21.9 (2q, 2 Me(Leu)). CI-MS: 440 (100, [M+1]+).  Anal. calc. for C25H33N3O4 (439.56): 
C 68.31, H 7.57, N 9.56; found: C 68.13, H 7.70, N 9.35. 
2.3. H-Leu-Aib-N(Me)Ph (17). According to GP C, H2 was bubbled through a mixture 
of 16 (1.01 g, 2.29 mmol) and Pd/C (104 mg) in MeOH (23 ml) for 3 h: 663 mg (94%) of 17. 
Colorless crystals. M.p. 111.7–112.6° (CH2Cl2/hexane). [α]D = 2.4 (c = 0.96, EtOH). IR 
(CHCl3): 3400m, 3325m, 3290m, 3030w, 2990w, 2950m, 2930m, 2870m, 1660s, 1635s, 
1600m, 1510m, 1495m, 1470m, 1450m, 1440m, 1395m, 1385m, 1375m, 1090m, 770m, 710m. 
1H-NMR (CD3OD): 7.52–7.20 (m, 5 arom. H); 3.26 (s, MeN); 3.02 (br. s, CH(2)(Leu)); 1.84–
1.56, 1.44–1.12 (2m, CH2(3)(Leu), CH(4)(Leu)); 1.48 (s, Me2C); 0.93, 0.89 (2d, J = 6.5, 2 
Me(Leu)). 13C-NMR (CD3OD): 177.3, 175.1 (2s, 2 CO(amide)); 146.1 (s, 1 arom. C); 130.5, 
128.8, 128.5 (3d, 5 arom. CH); 58.3 (s, Me2C); 54.2 (d, C(2)(Leu)); 45.0 (t, C(3)(Leu)); 41.6 
(q, MeN); 27.4, 27.1 (2q, Me2C); 25.6 (d, C(4)(Leu)); 23.7, 22.1 (2q, 2 Me(Leu)). CI-MS: 306 
(100, [M+1]+).  Anal. calc. for C17H27N3O2 (305.42): C 66.85, H 8.91, N 13.76; found: C 
66.73, H 9.00, N 13.95. 
2.4. Z-Gly-Aib-Leu-Aib-N(Me)Ph. According to GP D, a soln. of 15 (1.00 g, 3.40 
mmol) and 17 (1.09 g, 3.58 mmol) in DMF (6 ml) was treated with DCC (702 mg, 3.40 
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mmol) and ZnCl2 (924 mg, 6.78 mmol) for 18.5 h: 1.56 g (79%) of Z-Gly-Aib-Leu-Aib-
N(Me)Ph. Colorless solid. M.p. 85.1–86.1°. [α]D = 22.6 (c = 0.92, EtOH). IR (CHCl3): 
3420w, 3340w, 3000m, 2960w, 2940w, 2880w, 1670s (br), 1595m, 1510m, 1470m, 1455m, 
1385m, 1365m, 1265m, 1170w, 1120w, 705m. 1H-NMR (CD3OD): 7.45–7.17 (m, 10 arom. 
H); 5.17, 5.04 (AB, J = 12.5, PhCH2O); 4.36–4.20 (m, CH(2)(Leu)); 3.83, 3.65 (AB, J = 16.3, 
CH2(Gly)); 3.29 (s, MeN); 1.84–1.55 (m, CH2(3)(Leu), CH(4)(Leu)); 1.52, 1.47, 1.42 (3s, 2 
Me2C); 0.96, 0.89 (2d, J = 6.5, 2 Me(Leu)). 13C-NMR (CD3OD): 176.7, 175.5, 174.2, 172.3 
(4s, 4 CO(amide)); 159.4 (s, CO(urethane)); 146.8, 137.9 (2s, 2 arom. C); 130.4, 129.5, 129.1, 
128.8, 128.3 (5d, 10 arom. CH); 67.9 (t, PhCH2O); 58.3, 58.0 (2s, 2 Me2C); 53.3 (d, 
C(2)(Leu)); 45.5 (t, C(2)(Gly)); 41.2 (q, MeN); 40.8 (t, C(3)(Leu)); 26.9, 26.8 (2q, Me2C); 
26.1 (d, C(4)(Leu)); 24.3, 23.8, 21.2 (3q, Me2C, 2 Me(Leu)). CI-MS: 475 (100, [M–
Ph(Me)N]+).  Anal. calc. for C31H43N5O6 (581.72): C 64.01, H 7.45, N 12.04; found: C 64.00, 
H 7.59, N 11.82. 
2.5. H-Gly-Aib-Leu-Aib-N(Me)Ph (18). According to GP C, a mixture of Z-Gly-Aib-
Leu-Aib-N(Me)Ph (1.35 g, 2.32 mmol) and Pd/C (215 mg) in MeOH (20 ml) was treated with 
H2 for 21.5 h: 1.04 g (quant.) of 18. Colorless foam. M.p. 85.7–86.5°. [α]D = –13.3 (c = 1.03, 
EtOH). IR (CHCl3): 3420w, 3340m, 3005m, 2960m, 2870w, 1665s, 1590m, 1515s, 1495s, 
1470m, 1455m, 1430m, 1390m, 1370m, 1270m, 1240m, 1190m, 1170m, 1120m, 705m. 1H-
NMR (CD3OD): 7.45–7.16 (m, 5 arom. H); 4.22 (br. s, CH(2)(Leu)); 3.28 (s, MeN); 3.26 (s, 
CH2(Gly)); 1.76–1.36 (m, CH2(3)(Leu), CH(4)(Leu)); 1.49, 1.47, 1.45 (3s, 2 Me2C); 0.95, 
0.90 (2d, J = 5.5, 2 Me(Leu)). 1H-NMR (CDCl3): 7.71 (s, NH); 7.48–7.20 (m, 5 arom. H); 
7.04 (s, NH); 6.86 (d, J = 8.6, NH); 4.34–4.20 (m, CH(2)(Leu)); 3.31 (s, CH2(Gly)); 3.26 (s, 
MeN); 1.85–1.40 (m, CH2(3)(Leu), CH(4)(Leu)); 1.53, 1.52, 1.47, 1.36 (4s, 2 Me2C); 0.93, 
0.90 (2d, J = 6.5, 2 Me(Leu)). 13C-NMR (CD3OD): 176.6, 175.4, 174.6, 174.0 (4s, 4 
CO(amide)); 146.5 (s, 1 arom. C); 130.4, 128.4 (2d, 5 arom. CH); 58.5, 57.7 (2s, 2 Me2C); 
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52.9 (d, C(2)(Leu)); 45.1 (t, C(2)(Gly)); 41.3 (q, MeN); 41.1 (t, C(3)(Leu)); 26.9, 26.5, 26.0 
(3q, 2 Me2C); 24.8 (d, C(4)(Leu)); 23.8, 21.5 (2q, 2 Me(Leu)). CI-MS: 448 (5, [M+1]+), 341 
(100, [M–Ph(Me)N]+). Anal. calc. for C23H37N5O4 (447.58): C 61.72, H 8.33, N 15.65; found: 
C 61.72, H 8.29, N 15.43. 
2.6. Z-Aib-Gly-Aib-Leu-Aib-N(Me)Ph. According to GP D, to a soln. of Z-Aib-OH 
(202 mg, 0.85 mmol) in DMF (1.5 ml) were added DCC (176 mg, 0.85 mmol), HOBt  (129 
mg, 0.96 mmol), CSA (12 mg), and 18 (437 mg, 0.98 mmol), and the mixture was stirred for 
24.5 h: 478 mg (84%) of Z-Aib-Gly-Aib-Leu-Aib-N(Me)Ph. Colorless crystals. M.p. 193.8–
194.7° (CH2Cl2/Et2O/hexane). [α]D = 19.1 (c = 0.92, EtOH). IR (CHCl3): 3440w, 3320m, 
3000m, 2960w, 2870w, 1710m, 1660s, 1590w, 1530m, 1500m, 1470w, 1455w, 1385w, 1365w, 
1330w, 1265m, 1190w, 1170w, 1090m, 700w. 1H-NMR (CDCl3): 7.66 (br. s, NH); 7.55–7.10 
(m, 10 arom. H, 3 NH); 6.09 (s, NH); 5.12, 5.06 (AB, J = 12.5, PhCH2O); 4.42–4.28 (m, 
CH2(Leu)); 3.46–3.38 (m, CH2(Gly)); 3.32 (s, MeN); 1.90–1.45 (m, CH2(3), CH(4)(Leu)); 
1.53, 1.45, 1.41, 1.33 (4s, 3 Me2C); 0.92, 0.86 (2d, J = 6.4, 2 Me(Leu)). 13C-NMR (CDCl3): 
177.3, 174.8, 174.0, 172.6, 170.3 (5s, 5 CO(amide)); 156.1 (s, CO(urethane)); 145.8, 136.3 
(2s, 2 arom. C); 129.1, 128.5, 128.1, 127.5, 127.2, 126.7 (6d, 10 arom. CH); 66.7 (t, 
PhCH2O); 57.1, 56.9, 56.6 (3s, 3 Me2C); 52.2 (d, C(2)(Leu)); 45.4 (t, C(2)(Gly)); 40.4 (q, 
MeN); 40.0 (t, C(3)(Leu)); 27.3, 26.3, 25.8, 25.0, 23.5, 23.4, 20.7 (6q and 1d, 3 Me2C, 
C(4)(Leu), 2 Me(Leu)). ESI-MS: 705 (40, [M+K]+), 689 (100, [M+Na]+), 684 (56), 667 (21, 
[M+1]+). Anal. calc. for C35H50N6O7 (666.82): C 63.04, H 7.56, N 12.60; found: C 63.12, H 
7.72, N 12.52. 
2.7. Z-Aib-Gly-Aib-Leu-Aib-OH (10). According to GP B, a soln. of Z-Aib-Gly-Aib-
Leu-Aib-N(Me)Ph (195 mg, 0.29 mmol) in 3N HCl (6 ml) was stirred for 30 h: 154 mg (91%) 
of 10. Colorless crystals. M.p. 194.7–195.7° (CH2Cl2/hexane). [α]D = 1.0 (c = 1.04, EtOH). 
IR (KBr): 3320m (br), 3050w, 2990w, 2930w, 2850w, 1740m, 1710m, 1670s, 1630s, 1575m, 
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1550m, 1535m, 1470w, 1455w, 1390w, 1370w, 1310w, 1270m, 1245m, 1180w, 1090w, 
1020w, 740w. 1H-NMR (CDCl3): 8.68, 7.90, 7.77, 7.66, 7.64 (5s, 5 NH); 7.45–7.25 (m, 5 
arom. H); 5.12 (s, PhCH2O); 4.32–4.20 (m, CH(2)(Leu)); 3.77, 3.68 (AB of ABX, JAB = 16.7, 
JAX = 5.8, JBX = 4.7, CH2(Gly)); 1.85–1.55 (m, CH2(3)(Leu), CH(4)(Leu)); 1.49, 1.48, 1.45, 
1.42 (4s, 3 Me2C); 0.94, 0.86 (2d, J = 5.3, 2 Me(Leu)). 13C-NMR (CD3OD): 178.8, 177.7, 
177.2, 174.3, 172.5 (5s, 5 CO(amide)); 158.0 (s, CO(urethane)); 138.1 (s, 1 arom. C); 129.5, 
129.0, 128.5 (3d, 5 arom. CH); 67.7 (t, PhCH2O); 58.2, 57.6, 57.1 (3s, 3 Me2C); 53.6 (d, 
C(2)(Leu)); 45.5 (t, C(2)(Gly)); 40.7 (t, C(3)(Leu)); 27.1, 26.3, 25.9, 25.7, 25.0, 24.7, 24.4, 
23.7, 21.1 (8q and 1d, 3 Me2C, C(4)(Leu), 2 Me(Leu)). ESI-MS: 638 (7), 622 (20), 616 (48, 
[M+K]+), 600 (100, [M+Na]+), 578 (4, [M+1]+). Anal. calc. for C28H43N5O8 (577.68): C 58.22, 
H 7.50, N 12.12; found: C 58.31, H 7.55, N 12.16. 
Suitable crystals for an X-ray crystal-structure determination were obtained from 
CH2Cl2/Et2O/hexane by slow evaporation of the solvent. 
2.8. Ac-Aib-Gly-Aib-Leu-Aib-N(Me)Ph. According to GP D, to a soln. of Ac-Aib-OH 
(100 mg, 0.68 mmol) [31] in DMF (2 ml) were added DCC (143 mg, 0.69 mmol), HOBt  (105 
mg, 0.78 mmol), CSA (10 mg), and 18 (355 mg, 0.79 mmol), and the mixture was stirred for 
22.5 h: 209 mg (52%) of Ac-Aib-Gly-Aib-Leu-Aib-N(Me)Ph. Colorless crystals. M.p. 232.7–
233.5° (CH2Cl2/hexane). 1H-NMR (CD3OD): 7.44–7.18 (m, 5 arom. H); 4.32–4.18 (m, 
CH(2)(Leu)); 3.72, 3.66 (AB, J = 16.8, CH2(Gly)); 3.31 ( br. s, MeN); 1.99 (s, MeCO); 1.92–
1.60 (m, CH2(3)(Leu), CH(4)(Leu)); 1.54, 1.53, 1.50, 1.46, 1.45, 1.41 (6s, 3 Me2C); 0.95, 0.88 
(2d, J = 5.8, 2 Me(Leu)). ESI-MS: 613 (20, [M+K]+), 597 (100, [M+Na]+), 575 (6, [M+1]+).  
2.9. Ac-Aib-Gly-Aib-Leu-Aib-OH. According to GP B, a soln. of Ac-Aib-Gly-Aib-Leu-
Aib-N(Me)Ph (99 mg, 0.17 mmol) in 3N HCl (2 ml) was stirred for 7.5 h: 19 mg (23%) of Ac-
Aib-Gly-Aib-Leu-Aib-OH. Colorless crystals. 1H-NMR (CD3OD): 4.30–4.22 (m, CH(2)(Leu)); 
3.76, 3.68 (AB, J = 16.8, CH2(Gly)); 1.98 (s, MeCO); 1.80–1.30 (m, CH2(3)(Leu), 
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CH(4)(Leu)); 1.51, 1.49, 1.47, 1.46, 1.44, 1.42 (6s, 3 Me2C); 0.94, 0.87 (2d, J = 6.1, 2 
Me(Leu)). ESI-MS: 524 (40, [M+K]+), 508 (100, [M+Na]+).  
3. Preparation of the Octapeptide Z-Gln-Aib-Aib-Aib-Ala-Ala-Aib-Pro-OH (19). 3.1. 
Z-Ala-Ala-Aib-N(Me)Ph. According to GP A, Z-Ala-Ala-OH (2.34 g, 8.00 mmol) in THF (50 
ml) was treated with 2a (1.98 g, 11.00 mmol) for 24 h: 3.66 g (98%) of Z-Ala-Ala-Aib-
N(Me)Ph. Colorless crystals. M.p. 128.3–128.9° (AcOEt/hexane). [α]D = –15.9 (c = 0.74, 
EtOH). IR (CHCl3): 3430w, 3340w, 3070w, 3010m, 2980w, 2940w, 1715s, 1670s, 1595m, 
1495s, 1455m, 1390m, 1370w, 1290w, 1240m, 1120w, 1070w, 1030w, 705m. 1H-NMR 
(CD3OD): 7.46–7.12 (m, 10 arom. H); 5.15, 5.07 (AB, J = 12.6, PhCH2O); 4.24–3.86 (m, 2 
CH(2)(Ala)); 3.20 (s, MeN); 1.48, 1.45 (2s, Me2C); 1.36 (d, J = 7.3, Me(Ala)); 1.22 (d, J = 
6.8, Me(Ala)). 13C-NMR (CD3OD): 175.3, 173.6 (2s, 2 CO(amide)); 158.7 (s, CO(urethane)); 
146.4, 138.1 (2s, 2 arom. C); 130.9, 129.8, 129.3, 129.0, 128.6 (5d, 10 arom. CH); 68.0 (t, 
PhCH2O); 58.6 (s, Me2C); 52.8, 50.0 (2d, 2 C(2)(Ala)); 41.8 (q, MeN); 27.4, 27.2 (2q, Me2C); 
18.8, 18.4 (2q, 2 Me(Ala)). CI-MS: 362 (100, [M+1–PhCH2O]+). Anal. calc. for C25H32N4O5 
(468.56): C 64.09, H 6.88, N 11.96; found: C 63.84, H 6.87, N 11.94. 
3.2. Z-Ala-Ala-Aib-OH (20). According to GP B, a soln. of Z-Ala-Ala-Aib-N(Me)Ph 
(2.07 g, 4.42 mmol) in 3N HCl (45 ml) was stirred for 26 h: 1.58 g (94%) of 20. Colorless 
crystals. M.p. 82.5–83.2° (MeOH/Et2O/hexane). [α]D = –42.1 (c = 1.02, EtOH). IR (KBr): 
3300w (br), 3070m, 2990m, 2940m, 1730s, 1650s, 1535s, 1455s, 1385w, 1370w, 1260s, 
1170m, 1075m, 1030m, 740m, 700m. 1H-NMR (CD3OD): 7.42–7.22 (m, 5 arom. H); 5.09 (s, 
PhCH2O); 4.34, 4.11 (2q, J = 7.1, 2 CH(2)(Ala)); 1.47, 1.46 (2s, Me2C); 1.34 (d, J = 7.1, 2 
Me(Ala)). 13C-NMR (CD3OD): 177.7 (s, COOH); 175.3, 173.8 (2s, 2 CO(amide)); 158.4 (s, 
CO(urethane)); 138.1 (s, 1 arom. C); 129.5, 129.0, 128.8 (3d, 5 arom. CH); 67.7 (t, PhCH2O); 
57.0 (s, Me2C); 52.3, 50.1 (2d, 2 C(2)(Ala)); 25.2 (q, Me2C); 18.1, 17.9 (2q, 2 Me(Ala)). CI-
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MS: 380 (100, [M+1]+). Anal. calc. for C18H25N3O6 (379.42): C 56.98, H 6.64, N 11.08; 
found: C 56.90, H 6.58, N 11.14. 
3.3. Z-Ala-Ala-Aib-Pro-OtBu (21). According to GP D, DCC (710 mg, 3.43 mmol) 
was added to a stirred soln. of 20 (1.30 g, 3.43 mmol) in DMF (7 ml). After 5 min, HOBt (510 
mg, 3.78 mmol), CSA (50 mg), H-Pro-OtBu dibenzenesulfimide salt (1.85 g, 3.95 mmol), and 
Et3N (397 mg, 3.93 mmol) in DMF (4 ml) were added, and the mixture was stirred for 25.5 h: 
1.64 g (89%) of 21. Colorless crystals. M.p. 185.3–186.4° (CH2Cl2/hexane). [α]D = –85.2 (c = 
1.04, EtOH). IR (CHCl3): 3420w, 3340w, 3040w, 3010m, 2980m, 2940w, 1725s, 1690m, 
1670s, 1625m, 1500s, 1455m, 1420m, 1380w, 1370m, 1340w, 1290w, 1240m, 1150m, 1090w, 
1070w, 1030w, 700w. 1H-NMR (CD3OD): 7.39–7.26 (m, 5 arom. H); 5.11, 5.07 (AB, J = 12.3, 
PhCH2O); 4.35 (q, J = 7.1, CH(2)(Ala)); 4.26 (dd, J = 8.5, 3.3, CH(2)(Pro)); 4.09 (q, J = 7.1, 
CH(2)(Ala)); 3.66–3.44 (m, CH2(5)(Pro)); 2.07–1.72 (m, CH2(3)(Pro), CH2(4)(Pro)); 1.44 (s, 
Me2C); 1.43 (s, Me3C); 1.33, 1.32 (2d, J = 7.1, 2 Me(Ala)). 13C-NMR (CD3OD): 175.7, 174.0, 
173.8 (3s, 4 CO); 158.6 (s, CO(urethane)); 138.4 (s, 1 arom. C); 129.8, 129.3, 129.0 (3d, 5 
arom. CH); 82.5 (s, Me3C); 67.9 (t, PhCH2O); 63.4 (d, C(2)(Pro)); 57.7 (s, Me2C); 52.5, 50.2 
(2d, 2 C(2)(Ala)); 49.5 (t, C(5)(Pro)); 29.2, 26.4 (2t, C(4)(Pro), C(3)(Pro)); 28.6 (q, Me3C); 
25.9, 25.1 (2q, Me2C); 18.4 (q, 2 Me(Ala)). FAB-MS: 533 (15, [M+1]+), 362 (83, [M–(Pro-
OtBu)]+). Anal. calc. for C27H40N4O7 (532.64): C 60.89, H 7.57, N 10.52; found: C 60.78, H 
7.73, N 10.66. 
Suitable crystals for an X-ray crystal-structure determination were obtained from 
CH2Cl2/hexane by slow evaporation of the solvent. 
3.4. H-Ala-Ala-Aib-Pro-OtBu (12). According to GP C, a stirred mixture of 21 (1.10 g, 
2.07 mmol) and Pd/C (154 mg) in MeOH (20 ml) was treated with H2 for 18.5 h: 816 mg 
(98%) of 12. Colorless crystals. M.p. 116.4–117.4° (MeOH/AcOEt/hexane). 1H-NMR 
(CD3OD): 4.36 (q, J = 7.2, CH(2)(Ala)); 4.32–4.25 (m, CH(2)(Pro)); 3.70–3.53 (m, 
22 
 
CH2(5)(Pro)); 3.41 (q, J = 6.9, CH(2)(Ala)); 2.07–1.75 (m, CH2(3)(Pro), CH2(4)(Pro)); 1.45, 
1.44, 1.43 (3s, Me2C, Me3C); 1.33 (d, J = 7.2,  Me(Ala)); 1.24 (d, J = 6.9,  Me(Ala)). 13C-
NMR (CD3OD): 177.9 (s, CO(ester)); 173.9, 173.7, 173.5 (3s, 3 CO(amide)); 82.2 (s, Me3C); 
63.0 (d, C(2)(Pro)); 57.3 (s, Me2C); 51.4, 49.6 (2d, 2 C(2)(Ala)); 49.2 (t, C(5)(Pro)); 28.9, 
26.6 (2t, C(4)(Pro), C(3)(Pro)); 28.2 (q, Me3C); 25.6, 24.7 (2q, Me2C); 18.3 (q, 2 Me(Ala)). 
ESI-MS: 437 (4, [M+K]+), 421 (9, [M+Na]+), 399 (100, [M+1]+).  
3.5. Z-Gln(Trt)-Aib-N(Me)Ph. According to GP A, a soln. of Z-Gln(Trt)-OH (23a, 3.01 
g, 5.76 mmol) in THF (25 ml) was treated with 2a (1.25 g, 7.18 mmol) for 45 h: 3.59 g (89%) 
of Z-Gln(Trt)-Aib-N(Me)Ph. Colorless foam. M.p. 89.2–90.1°. [α]D = –1.2 (c = 0.84, EtOH). 
IR (CHCl3): 3430w, 3060w, 3010w, 2940w, 1715m, 1680m, 1635m, 1595w, 1495s, 1450w, 
1420w, 1390w, 1365w, 1245w, 1195w, 1120w, 1050w, 700m. 1H-NMR (CDCl3): 7.43–7.06 
(m, 25 arom. H); 6.56 (s, NH); 5.76 (br. d, J = 7.1, NH); 5.16, 5.06 (AB, J = 12.2, PhCH2O); 
3.76–3.63 (m, CH(2)(Gln)); 3.20 (s, MeN); 2.55–2.30 (m, CH2(4)(Gln)); 2.00–1.70 (m, 
CH2(3)(Gln)); 1.37, 1.28 (2s, Me2C). 13C-NMR (CD3OD): 175.3, 174.5, 173.3 (3s, 3 
CO(amide)); 158.5 (s, CO(urethane)); 146.4, 146.3, 138.5 (3s, 5 arom. C); 130.8, 130.3, 
129.8, 129.4, 129.0, 128.8, 128.0 (7d, 25 arom. CH); 71.9 (s, Ph3C); 68.0 (t, PhCH2O); 58.7 
(s, Me2C); 55.6 (d, C(2)(Gln)); 41.7 (q, MeN); 33.7, 29.9 (2t, C(4)(Gln), C(3)(Gln)); 27.2 (q, 
Me2C). CI-MS: 589 (15, [M–PhCH2O]+), 243 (100, Trt+). ESI-MS: 735 (70, [M+K]+), 719 
(100, [M+Na]+), 697 (17, [M+1]+). Anal. calc. for C43H44N4O5 (696.85): C 74.12, H 6.36, N 
8.04; found: C 73.87, H 6.34, N 7.82. 
3.6. Z-Gln(Trt)-Aib-OH. According to GP B, a soln. of Z-Gln(Trt)-Aib-N(Me)Ph (4.93 
g, 7.08 mmol) in 3N HCl (80 ml) was stirred for 8 h: 4.25 g (98%) of Z-Gln(Trt)-Aib-OH. 
Colorless crystals. M.p. 121.6–122.5° (CH2Cl2/hexane). [α]D = –6.3 (c = 0.87, EtOH). IR 
(KBr): 3430m, 3340m, 3080w, 3060w, 3030w, 2940w, 1740w, 1700m (br), 1650s, 1520m, 
1505m, 1495m, 1470w, 1400w, 1365w, 1240w, 1220w, 1150w, 1055w, 1000w, 700m. 1H-
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NMR (CDCl3): 8.57 (s, NH); 8.13 (s, NH); 7.38–7.13 (m, 20 arom. H); 5.11, 5.06 (AB, J = 
12.8, PhCH2O); 4.13–4.00 (m, CH(2)(Gln)); 2.54–2.31 (m, CH2(4)(Gln)); 2.08–1.91, 1.91–
1.72 (2m, CH2(3)(Gln)); 1.47, 1.42 (2s, Me2C). 13C-NMR (CD3OD): 177.9 (s, COOH); 174.7, 
173.8 (2s, 2 CO(amide)); 158.6 (s, CO(urethane)); 146.2, 138.4 (2s, 4 arom. C); 130.3, 129.8, 
129.3, 129.2, 129.0, 128.1 (6d, 20 arom. CH); 71.9 (s, Ph3C); 68.1 (t, PhCH2O); 57.5 (s, 
Me2C); 55.9 (d, C(2)(Gln)); 33.9, 29.6 (2t, C(4)(Gln), C(3)(Gln)); 25.8, 25.3 (2q, Me2C). ESI-
MS: 646 (100, [M+K]+), 630 (68, [M+Na]+), 628 (90). Anal. calc. for C36H37N3O6 (607.71): C 
71.15, H 6.14, N 6.92; found: C 71.34, H 6.07, N 6.91. 
3.7. Z-Gln(Trt)-Aib-Aib-N(Me)Ph. According to GP A, a soln. of Z-Gln(Trt)-Aib-OH 
(3.98 g, 6.55 mmol) in CH2Cl2 (40 ml) and DMF (12 ml) was treated with 2a (1.60 g, 9.16 
mmol) for 36 h: 4.48 g (87%) of Z-Gln(Trt)-Aib-Aib-N(Me)Ph. Colorless foam. M.p. 111.5–
112.0°. [α]D = –2.0 (c = 1.06, EtOH). IR (CHCl3): 3420w, 3350w, 3040w, 3005m, 2930w, 
1715m, 1670m, 1630m, 1595m, 1495s, 1450m, 1390m, 1360m, 1240m, 1200w, 1020w, 700m. 
1H-NMR (CDCl3): 7.57 (s, NH); 7.42–7.06 (m, 25 arom. H, NH); 6.64 (s, NH); 5.96 (br. s, 
NH); 5.15, 5.06 (AB, J = 12.1, PhCH2O); 4.03 (dd, J = 12.3, 6.3, CH(2)(Gln)); 3.15 (s, MeN); 
2.68–2.52, 2.52–2.36 (2m, CH2(4)(Gln)); 2.15–2.00 (m, CH2(3)(Gln)); 1.40, 1.37, 1.31 (3s, 2 
Me2C). 13C-NMR (CD3OD): 176.2, 175.7, 174.5, 174.2 (4s, 4 CO(amide)); 158.9 (s, 
CO(urethane)); 147.0, 146.2, 138.6 (3s, 5 arom. C); 130.6, 130.3, 129.8, 129.3, 129.0, 128.9, 
128.8, 128.6, 128.1 (9d, 25 arom. CH); 71.9 (s, Ph3C); 67.9 (t, PhCH2O); 59.0, 58.4 (2s, 2 
Me2C); 56.7 (d, C(2)(Gln)); 41.5 (q, MeN); 34.0, 28.6 (2t, C(4)(Gln), C(3)(Gln)); 26.7, 26.6, 
26.4, 25.3 (4q, 2 Me2C). ESI-MS: 820 (10, [M+K]+), 804 (100, [M+Na]+). Anal. calc. for 
C47H51N5O6 (781.96): C 72.19, H 6.57, N 8.96; found: C 72.04, H 6.78, N 9.03. 
3.8. Z-Gln(Trt)-Aib-Aib-OH. According to GP B, a soln. of Z-Gln(Trt)-Aib-Aib-
N(Me)Ph (1.00 g, 1.28 mmol) in 3N HCl (16 ml) was stirred for 6.5 h: 889 mg (quant.) of Z-
Gln(Trt)-Aib-Aib-OH. Colorless foam. M.p. 105.5–106.3°. [α]D = –3.9 (c = 1.01, EtOH). IR 
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(KBr): 3350m (br), 3060w, 3030w, 2980w, 2930w, 1710m, 1660s, 1530m, 1515m, 1450m, 
1390w, 1365w, 1315w, 1245m, 1155w, 1080w, 1000w, 700m. 1H-NMR (CDCl3): 7.50–7.00 
(m, 20 arom. H, 2 NH); 6.38 (d, J = 5.5, NH); 5.09, 5.02 (AB, J = 12.2, PhCH2O); 4.02–3.88 
(m, CH(2)(Gln)); 2.60–2.30 (m, CH2(4)(Gln)); 2.08–1.78 (m, CH2(3)(Gln)); 1.45, 1.43, 1.35, 
1.28 (4s, 2 Me2C). 13C-NMR (CD3OD): 178.3 (s, COOH); 176.1, 174.5, 174.3 (3s, 3 
CO(amide)); 158.8 (s, CO(urethane)); 146.2, 138.5 (2s, 4 arom. C); 130.3, 129.8, 129.3, 
129.0, 128.1 (5d, 20 arom. CH); 71.9 (s, Ph3C); 68.0 (t, PhCH2O); 58.2, 57.5 (2s, 2 Me2C); 
56.6 (d, C(2)(Gln)); 34.0, 28.6 (2t, C(4)(Gln), C(3)(Gln)); 26.1, 25.8, 25.7, 25.1 (4q, 2 Me2C). 
ESI-MS: 738 (9, [M+2Na]+), 731 (18, [M+K]+), 715 (100, [M+Na]+). FAB-MS: 693 (38, 
[M+1]+), 243 (100). Anal. calc. for C40H44N4O7 (692.82): C 69.35, H 6.40, N 8.09; found: C 
69.10, H 6.59, N 7.88. 
3.9. Z-Gln(Trt)-Aib-Aib-Aib-N(Me)Ph. According to GP A, a soln. of Z-Gln(Trt)-Aib-
Aib-OH (2.08 g, 3.00 mmol) in CH2Cl2 (25 ml) was treated with 2a (630 mg, 3.62 mmol) for 
42 h: 2.34 g (89%) of Z-Gln(Trt)-Aib-Aib-Aib-N(Me)Ph. Colorless foam. M.p. 199.0–199.7°. 
[α]D = –19.6 (c = 1.07, EtOH). IR (CHCl3): 3420w, 3340w, 3050w, 2995w, 2930w, 1675s, 
1590w, 1490s, 1450w, 1390w, 1360w, 1240w, 1030w, 700m. 1H-NMR (CDCl3): 7.40–7.12 
(m, 25 arom. H, NH); 7.05, 6.75, 6.66, 6.31 (4s, 4 NH); 5.10, 5.05 (AB, J = 12.3, PhCH2O); 
3.95–3.82 (m, CH(2)(Gln)); 3.30 (s, MeN); 2.66–2.52, 2.52–2.36 (2m, CH2(4)(Gln)); 2.12–
1.86 (m, CH2(3)(Gln)); 1.46, 1.44, 1.31, 1.26 (4s, 3 Me2C). 13C-NMR (CD3OD): 176.5, 175.7, 
175.6, 174.6, 174.1 (5s, 5 CO(amide)); 147.0, 145.9, 138.0 (3s, 5 arom. C); 130.2, 129.9, 
129.5, 129.1, 128.8, 128.7, 128.2, 128.0, 127.8 (9d, 25 arom. CH); 71.6 (s, Ph3C); 67.8 (t, 
PhCH2O); 58.3, 58.0, 57.7 (3s, 3 Me2C); 56.3 (d, C(2)(Gln)); 41.0 (q, MeN); 33.5, 27.8 (2t, 
C(4)(Gln), C(3)(Gln)); 26.8, 26.5, 26.2, 25.9, 25.0, 24.5 (6q, 3 Me2C); CO(urethane) not 
detected. ESI-MS: 906 (30, [M+K]+), 890 (100, [M+Na]+). Anal. calc. for C51H58N6O7 
(867.06): C 70.65, H 6.74, N 9.69; found: C 70.74, H 6.65, N 9.90. 
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3.10. Z-Gln(Trt)-Aib-Aib-Aib-OH (11a). According to GP B, a soln. of Z-Gln(Trt)-
Aib-Aib-Aib-N(Me)Ph (1.31 g, 1.51 mmol) in 3N HCl (16 ml) was stirred for 5 h: 1.17 g 
(quant.) of Z-Gln(Trt)-Aib-Aib-Aib-OH. Colorless foam. M.p. 119.0–120.0°. [α]D = –1.9 (c = 
1.09, EtOH). IR (KBr): 3660w, 3420m, 3310m, 3050w, 2980m, 2940w, 2870w, 1725m, 
1705m, 1670s, 1600w, 1545m, 1530m, 1510m, 1500m, 1470m, 1445m, 1375m, 1365m, 
1315m, 1275m, 1240m, 1165m, 1080w, 1050w, 1000w, 700m. 1H-NMR (CDCl3): 7.40 (s, 
NH); 7.38–7.08 (m, 20 arom. H, 1 NH); 7.01, 6.97 (2s, 2 NH); 6.53 (d, J = 4.5, NH); 5.11, 
5.04 (AB, J = 12.3, PhCH2O); 3.95–3.80 (m, CH(2)(Gln)); 2.69–2.54, 2.54–2.40 (2m, 
CH2(4)(Gln)); 2.14–1.88 (m, CH2(3)(Gln)); 1.49, 1.47, 1.39, 1.38, 1.34, 1.23 (6s, 3 Me2C). 
13C-NMR (CD3OD): 178.1 (s, COOH); 176.4, 175.9, 174.6, 174.2 (4s, 4 CO(amide)); 158.7 
(s, CO(urethane)); 145.8, 138.1 (2s, 4 arom. C); 129.9, 129.5, 129.1, 128.9, 128.7, 127.8 (6d, 
20 arom. CH); 71.6 (s, Ph3C); 68.0 (t, PhCH2O); 57.8, 57.7, 57.0 (3s, 3 Me2C); 56.2 (d, 
C(2)(Gln)); 33.5, 27.8 (2t, C(4)(Gln), C(3)(Gln)); 26.5, 26.1, 25.8, 24.8, 24.5, 24.3 (6q, 3 
Me2C). ESI-MS: 822 (100, [M+2Na]+), 800 (65, [M+Na]+). Anal. calc. for C44H51N5O8 
(777.92): C 67.94, H 6.61, N 9.00; found: C 67.82, H 6.79, N 8.89. 
3.11. Z-Gln(Trt)-Aib-Aib-Aib-Ala-Ala-Aib-Pro-OtBu (24). According to GP D, to a 
stirred soln. of 11a (250 mg, 0.32 mmol) in DMF (1.7 ml), DCC (68 mg, 0.33 mmol), HOBt 
(50 mg, 0.37 mmol), CSA (5 mg), and 12 (148 mg, 0.37 mmol) were added. The mixture was 
stirred for 24.5 h: 367 mg (97%) of 24. Colorless crystals. M.p. 146.1–147.5° 
(AcOEt/Et2O/hexane). 1H-NMR (CD3OD): 7.40–7.15 (m, 20 arom. H); 5.17, 5.09 (AB, J = 
12.6, PhCH2O); 4.36–4.26 (m, CH(2)(Ala), CH(2)(Pro)); 4.07 (q, J = 7.4, CH(2)(Ala)); 3.89 
(dd, J = 8.4, 6.2, CH(2)(Gln)); 3.74–3.65, 3.65–3.55 (2m, CH2(5)(Pro)); 2.56–2.46 (m, 
CH2(4)(Gln)); 2.16–1.76 (m, CH2(3)(Gln), CH2(3)(Pro), CH2(4)(Pro)); 1.54, 1.49, 1.46, 1.45, 
1.44, 1.42, 1.41, 1.34, 1.33, 1.31 (10s, 4 Me2C, Me3C, 2 Me(Ala)). ESI-MS: 1196 (10, 
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[M+K]+), 1180 (100, [M+Na]+). FAB-MS: 1180 (11, [M+Na]+), 987 (100, [M–(Pro-OtBu)]+),  
902 (23, [987–Aib]+), 831 (8, [902–Ala]+), 760 (9, [831–Ala]+). 
3.12. H-Gln(Trt)-Aib-Aib-Aib-Ala-Ala-Aib-Pro-OtBu (25). According to GP C, a 
stirred mixture of 24 (553 mg, 0.48 mmol) and Pd/C (73 mg) in MeOH (11 ml) was treated 
with H2 for 21 h: 475 mg (97%) of 25. Colorless foam. M.p. 150.2–151.3°. 1H-NMR 
(CD3OD): 7.32–7.06 (m, 15 arom. H); 4.36–4.27 (m, CH(2)(Ala), CH(2)(Pro)); 4.07 (q, J = 
7.4, CH(2)(Ala)); 3.73–3.65, 3.65–3.55 (2m, CH2(5)(Pro)); 3.25–3.18 (m, CH(2)(Gln)); 2.59–
2.40 (m, CH2(4)(Gln)); 2.16–1.66 (m, CH2(3)(Gln), CH2(3)(Pro), CH2(4)(Pro)); 1.60–1.24 (m, 
39 H). ESI-MS: 1046 (16, [M+Na]+), 1038 (17), 1024 (100, [M+1]+).  
3.13. Z-Gln-Aib-Aib-Aib-Ala-Ala-Aib-Pro-OH (19). According to GP E, a soln. of 24 
(300 mg, 0.26 mmol) in TFA (7 ml) was stirred for 3.15 h: 222 mg (quant.) of 19. Colorless 
crystals. M.p. 135.0–135.6° (AcOEt/Et2O/hexane). 1H-NMR (CD3OD): 7.89, 7.68 (2 br. s, 2 
NH); 7.42–7.18 (m, 5 arom. H); 5.18, 5.08 (AB, J = 12.6, PhCH2O); 4.42 (dd, J = 9.0, 4.0, 
CH(2)(Pro)); 4.33 (q, J = 7.1, CH(2)(Ala)); 4.15–4.02 (m, CH(2)(Ala); 3.95 (dd, J = 8.2, 6.2, 
CH(2)(Gln)); 3.72–3.48 (m, CH2(5)(Pro)); 2.37 (t, J = 7.4, CH2(4)(Gln)); 2.22–1.80 (m, 
CH2(3)(Gln), CH2(3)(Pro), CH2(4)(Pro)); 1.58–1.20 (m, 4 Me2C, 2 Me(Ala)). 13C-NMR: 
178.8, 177.9, 177.5, 176.9, 176.1, 174.8, 174.7, 174.1 (8s, COOH, 8 CO(amide)); 158.9 (s, 
CO(urethane)); 138.4 (s, 1 arom. C); 130.0, 129.6, 129.1, 128.7, 127.8 (5d, 5 arom. CH); 67.9 
(t, PhCH2O); 62.1 (d, C(2)(Pro)); 57.8 (br. s, 4 Me2C); 57.6 (d, C(2)(Gln)); 52.5, 50.5 (2d, 2 
C(2)(Ala)); 49.6 (t, C(5)(Pro)); 32.4 (t, C(4)(Gln)); 29.1, 27.9, 26.8 (3t, C(3)(Gln), C(3)(Pro), 
C(4)(Pro)); 27.5, 27.0, 26.2, 25.5, 25.0, 24.1, 23.6 (7q, 4 Me2C); 17.5, 16.9 (2q, 2 Me(Ala)). 
ESI-MS: 1124 (5), 882 (100, [M+Na]+), 785 (9). FAB-MS: 882 (3, [M+Na]+), 745 (75, [M–
Pro]+), 660 (29, [745–Aib]+), 589 (35, [660–Ala]+), 518 ([589–Ala]+), 433 (92, [518–Aib]+), 
348 (100, [433–Aib]+), 263 (36, [348–Aib]+), 155 (26, [263–PhCH2O+1]+). 
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4. Preparation of the Pentapeptide H-Leu-Aib-D,L-Iva-Gln-Valol (13). 4.1. Z-Leu-Aib-
N(Me)Ph. According to GP A, Z-Leu-OH (3.03 g, 11.42 mmol) in Et2O (50 ml) was treated 
with 2a (2.20 g, 12.63 mmol) for 13 h: 4.99 g (99%) of Z-Leu-Aib-N(Me)Ph. Colorless 
crystals. M.p. 135.5–135.7° (Et2O/pentane). [α]D = –19.6 (c = 1.01, EtOH). IR (CHCl3): 
3430w, 3350w, 3070w, 3010m, 2960m, 1715m, 1680m, 1635m, 1595m, 1510s, 1495s, 1420m, 
1405m, 1390m, 1370m, 1240m, 1170m, 1120m, 1055m, 1030s, 705m. 1H-NMR (CD3OD): 
7.56–7.13 (m, 10 arom. H); 5.15, 5.06 (AB, J = 12.5, PhCH2O); 4.10–3.90 (m, CH(2)(Leu)); 
3.20 (s, MeN); 1.80–1.30 (m, CH2(3)(Leu), CH(4)(Leu)); 1.43 (s, Me2C); 0.92, 0.90 (2d, J = 
6.4, 2 Me(Leu)). 13C-NMR (CD3OD): 175.0, 174.1 (2s, 2 CO(amide)); 158.1 (s, 
CO(urethane)); 146.2, 138.1 (2s, 2 arom. C); 130.4, 130.0, 129.5, 129.3, 129.2, 129.0, 128.8, 
128.6, 128.5, 128.3 (10d, 10 arom. CH); 67.6 (t, PhCH2O); 58.3 (s, Me2C); 54.5 (d, 
C(2)(Leu));  42.5 (t,  C(3)(Leu)); 41.3 (q, MeN); 26.9, 25.8 (2q, Me2C); 26.6 (d, C(4)(Leu));  
23.6, 21.9 (2q, 2 Me(Leu)). CI-MS: 440 (100, [M+1]+). Anal. calc. for C25H33N3O4 (439.56): 
C 68.31, H 7.57, N 9.56; found: C 68.13, H 7.70, N 9.35. 
4.2. Z-Leu-Aib-OH (26). According to GP B, a soln. of Z-Leu-Aib-N(Me)Ph (3.50 g, 
7.97 mmol) in 3N HCl (80 ml) was stirred for 18 h: 2.58 g (92%) of 26. Colorless crystals. 
M.p. 118.8–119.8° (Et2O/hexane). [α]D = –23.7 (c = 1.12, EtOH). IR (KBr): 3430w, 3300w, 
3030w, 3005m, 2960m, 1720s, 1680s, 1515s, 1455m, 1390w, 1370w, 1290m, 1170m, 1120w, 
1050w, 1030w, 695m. 1H-NMR (CD3OD): 7.42–7.22 (m, 5 arom. H); 5.09 (s, PhCH2O); 
4.22–4.06 (m, CH(2)(Leu)); 1.86–1.50 (m, CH2(3)(Leu), CH(4)(Leu)); 1.47, 1.46 (2s, Me2C); 
0.94, 0.90 (2d, J = 6.4, 2 Me(Leu)). 13C-NMR (CD3OD): 177.9 (s, COOH); 174.8 (s, 
CO(amide)); 158.6 (s, CO(urethane)); 138.5 (s, 1 arom. C); 129.7, 129.3, 129.1 (3d, 5 arom. 
CH); 67.9 (t, PhCH2O); 57.3 (s, Me2C); 55.1 (d, C(2)(Leu)); 42.5 (t, C(3)(Leu)); 26.1 (d, 
C(4)(Leu)); 25.6, 25.3 (2q, Me2C); 23.6, 21.9 (2q, 2 Me(Leu)). CI-MS: 351 (100, [M+1]+). 
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Anal. calc. for C18H26N2O5 (350.42): C 61.70, H 7.48, N 7.99; found: C 61.60, H 7.51, N 
8.11. 
4.3. Z-Leu-Aib-D,L-Iva-N(Me)Ph. According to GP A, a soln. of 26 (3.46 g, 9.90 
mmol) in CH2Cl2 (55 ml) was treated with 2b (2.61 g, 13.86 mmol) for 18 h: 5.35 g (quant.) 
of Z-Leu-Aib- D,L-Iva-N(Me)Ph. Colorless foam. Colorless crystals were obtained after CC 
(SiO2, Et2O/hexane). M.p. 58.8–59.3°. [α]D = –6.3 (c = 0.89, EtOH). IR (CHCl3): 3450w, 
3010m, 2960m, 2940w, 2900w, 2880w, 1715m, 1670s, 1625m, 1595m, 1495m, 1455m, 1425s, 
1380m, 1365m, 1270w, 1170w, 1120w, 1050w, 1030w, 705m. 1H-NMR (CD3OD, 7:5 mixture 
of epimers): 7.43–7.17 (m, 10 arom. H); 5.20–5.03 (2 AB, J = 12.8, PhCH2O); 4.03 (t, J = 7.5, 
CH(2)(Leu)); 3.27, 3.21 (2s, MeN); 2.06–1.89 (m, 1 H of CH2(3)(Iva)); 1.85–1.62 (m, 1 H of 
CH2(3)(Iva), CH(4)(Leu)); 1.56–1.48 (m, CH2(3)(Leu)); 1.48, 1.43 (2s, Me2C); 1.39, 1.30 (2s, 
MeC(2)(Iva)); 0.96, 0.94 (2d, J = 6.5, 2 Me(Leu)); 0.86 (t, J = 7.2, MeCH2(Iva)). 13C-NMR 
(CD3OD): 175.8, 175.4, 174.7 (3s, 3 CO(amide)); 158.9 (s, CO(urethane)); 146.9, 138.7 (2s, 2 
arom. C); 130.7, 129.8, 129.3, 128.9, 128.7 (5d, 10 arom. CH); 67.7 (t, PhCH2O); 62.8 (s, 
C(2)(Iva)); 58.6 (s, Me2C); 55.8, 55.7 (2d, C(2)(Leu));  41.9 (t,  C(3)(Leu)); 41.6 (q, MeN); 
31.1, 31.0 (2t, C(3)(Iva)); 26.8, 26.5 (2q, Me2C); 26.1 (d, C(4)(Leu));  25.3, 25.0 (2q, 
MeC(2)(Iva)); 23.6, 22.5 (2q, 2 Me(Leu)); 9.1, 9.0 (2q, C(4)(Iva)). CI-MS: 432 (100, [M+1–
PhCH2O]+). Anal. calc. for C30H42N4O5 (538.69): C 66.89, H 7.86, N 10.40; found: C 66.75, 
H 8.06, N 10.20. 
The separation of the two diastereoisomers was achieved by prep. HPLC on a 
Nucleosil 100-7 column with hexane/CH2Cl2/EtOH 100:9:3 as the eluent. One of the epimers 
was obtained in pure form in ca. 10% yield, the second epimer was isolated as an 8:1 mixture 
with the first one. Data of the pure epimer: [α]D = 6.1 (c = 0.85, EtOH). 1H-NMR (CD3OD): 
7.45–7.20 (m, 10 arom. H); 5.15, 5.07 (AB, J = 12.7, PhCH2O); 4.03 (t, J = 7.5, CH(2)(Leu)); 
3.27 (s, MeN); 2.05–1.94 (m, 1 H of CH2(3)(Iva)); 1.85–1.62 (m, 1 H of CH2(3)(Iva), 
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CH(4)(Leu)); 1.56–1.50 (m, CH2(3)(Leu)); 1.48, 1.43 (2s, Me2C); 1.30 (s, MeC(2)(Iva)); 0.96, 
0.92 (2d, J = 6.6, 2 Me(Leu)); 0.86 (t,  J = 7.4, MeCH2). 
4.4. Z-Leu-Aib-D,L-Iva-OH (27). According to GP B, a soln. of Z-Leu-Aib- D,L-Iva-
N(Me)Ph (1.52 g, 2.83 mmol) in 3N HCl (30 ml) was stirred for 23 h: 703 mg (55%) of 27. 
Colorless crystals. M.p. 171.2–172.1° (AcOEt/hexane). IR (KBr): 3300m, 3060w, 3040w, 
2960m, 2870w, 1730s, 1710s, 1660s, 1525s, 1455m, 1385m, 1365m, 1315m, 1270m, 1245m, 
1165m, 1135w, 1045m, 1030w, 695m. 1H-NMR (CD3OD, mixture of epimers): 7.40–7.24 (m, 
5 arom. H); 5.15–5.02 (m, PhCH2O); 4.06 (t, J = 7.5, CH(2)(Leu)); 2.09–1.88, 1.88–1.61 (2m, 
CH(4)(Leu), CH2(3)(Iva)); 1.57–1.49 (m, CH2(3)(Leu)); 1.46, 1.43 (2s, Me2C); 1.42, 1.41 (2s, 
MeC(2)(Iva)); 0.95, 0.93 (2d, J = 6.5, 2 Me(Leu)); 0.81, 0.78 (2t, J = 7.5, MeCH2(Iva). 13C-
NMR (CD3OD): 177.7, 177.4 (2s, COOH); 175.9, 175.4 (2s, 2 CO(amide)); 158.8 (s, 
CO(urethane)); 138.6 (s, 1 arom. C); 129.8, 129.3, 129.0, 128.9, 128.8 (5d, 5 arom. CH); 
67.9, 67.8 (2t, PhCH2O); 61.6, 61.5 (2s, C(2)(Iva)); 58.5, 58.4 (2s, Me2C); 55.6 (d, 
C(2)(Leu)); 42.0 (t, C(3)(Leu)); 31.2, 30.4 (2t, C(3)(Iva)); 26.3, 26.1 (2d, C(4)(Leu)); 25.4, 
25.2 (2q, Me2C); 23.6, 22.4 (2q, 2 Me(Leu)); 23.0, 22.7 (2q, MeCH2(Iva)); 9.0, 8.9 (2q, 
C(4)(Iva)). CI-MS: 450 (100, [M+1]+). Anal. calc. for C23H35N3O6 (449.55): C 61.45, H 7.85, 
N 9.35; found: C 61.35, H 8.02, N 9.30. 
4.5. Z-Gln-Valol. To a soln. of Z-Gln-OH (504 mg, 1.80 mmol) in THF (12 ml) at –
12°, ethyl chloroformiat (0.17 ml, 1.78 mmol) and NMM (0.2 ml, 1.80 mmol) were added. 
After stirring for 4 min, L-Valinol (0.2 ml, 1.80 mmol) was added and the mixture was stirred 
at r.t. for 2 d. Then, the solid material was filtered and washed with cold AcOEt/CHCl3 and 
Et2O and recrystallized from MeOH: 582 mg (88%) of Z-Gln-Valol. Colorless crystals. M.p. 
189.8–190.5° (MeOH). [α]D = –23.7 (c = 0.86, MeOH). IR (KBr): 3430m, 3300s, 3090w, 
3060w, 3030w, 2960w, 2870w, 1680s, 1650s, 1535s, 1445w, 1415w, 1395w, 1370w, 1260m, 
1245m, 1140w, 1060w, 1045w, 700w. 1H-NMR (CD3OD): 7.42–7.22 (m, 5 arom. H); 5.08 (s, 
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PhCH2O); 4.14 (dd, J = 8.5, 5.7, CH(2)(Gln)); 3.76–3.46 (m, CH2(1)(Valol), CH(2)(Valol)); 
2.31 (t, J = 7.5, CH2(4)(Gln)); 2.18–1.72 (m, CH2(3)(Gln), CH(3)(Valol)); 0.93, 0.90 (2d, J = 
7.2, 2 Me(Valol)). 13C-NMR ((D6)DMSO): 174.0, 171.6 (2s, 2 CO(amide)); 156.0 (s, 
CO(urethane)); 137.2 (s, 1 arom. C); 128.5, 127.9, 127.8 (3d, 5 arom. CH); 65.5 (t, PhCH2O); 
61.5 (t, CH2OH); 55.7 (d, C(2)(Gln)); 54.7 (d, C(2)(Valol)); 31.8 (t, C(4)(Gln)); 28.3 (d, 
C(3)(Valol)); 28.1 (t, C(3)(Gln)); 19.8, 18.2 (2q, 2 Me(Valol)). CI-MS: 366 (100, [M+1]+). 
Anal. calc. for C18H27N3O5 (365.43): C 59.16, H 7.45, N 11.50; found: C 59.15, H 7.22, N 
11.27. 
4.6. H-Gln-Valol (28). According to GP C, H2 was bubbled through a soln. of Z-Gln-
Valol (530 mg, 1.45 mmol) in MeOH (31 ml) for 4.5 h: 328 mg (98%) of 28. Colorless foam. 
M.p. 144.5–145.1°. [α]D = –4.5 (c = 0.84, MeOH). IR (KBr): 3360s, 3300m (br), 3180m, 
2950m, 2870m, 1650s, 1620s, 1560m, 1450m, 1410m, 1380w, 1370w, 1280w, 1245w, 1200w, 
1150w, 1070m, 1035w, 710m (br). 1H-NMR (CD3OD): 3.76–3.48 (m, CH2(1)(Valol), 
CH(2)(Gln)); 3.42–3.32 (m, CH(2)(Valol)); 2.30 (t, J = 7.5, CH2(4)(Gln)); 2.06–1.72 (m, 
CH2(3)(Gln), CH(3)(Valol)); 0.96, 0.93 (2d, J = 6.5, 2 Me(Valol)). 13C-NMR (CD3OD): 
178.6, 177.5 (2s, 2 CO(amide)); 63.4 (t, C(1)(Valol)); 58.3 (d, C(2)(Gln)); 56.1 (d, 
C(2)(Valol)); 33.1 (t, C(4)(Gln)); 32.9 (t, C(3)(Gln)); 30.4 (d, C(3)(Valol)); 20.3, 19.2 (2q, 2 
Me(Valol)). CI-MS: 232 (100, [M+1]+). Anal. calc. for C10H21N3O3 (231.30): C 51.93, H 
9.15, N 18.17; found: C 51.68, H 8.89, N 17.98. 
4.7. Z-Leu-Aib-D,L-Iva-Gln-Valol. To a stirred soln. of 27 (1.10 g, 2.45 mmol) and 
DIEA (633 mg (4.90 mmol) in DMF (7 ml) at 0°, TBTU (788 mg, 2.45 mmol) and HOBt 
(366 mg, 2.71 mmol) were added. After 5 min, a soln. of 28 (646 mg, 2.79 mmol) in DMF (2 
ml) was added, and after 22 h, the mixture was treated according to GP D: 1.27 g (78%) of Z-
Leu-Aib-D,L-Iva-Gln-Valol. Colorless crystals. M.p. 88.4–89.3° (AcOEt/hexane). IR (KBr): 
3300m (br), 3060w, 3040w, 2960m, 2870w, 1705m, 1660s (br.), 1550m, 1535s, 1455m, 
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1385w, 1370w, 1310w, 1265m, 1220w, 1170w, 1120w, 1050w, 1030w, 695w. 1H-NMR 
(CD3OD, mixture of epimers): 7.47–7.33 (m, 5 arom. H); 5.18–5.03 (m, PhCH2O); 4.18–4.02 
(m, CH(2)(Gln), CH(2)(Leu)); 3.72–3.52 (m, CH2(1), CH(2)(Valol)); 2.43–2.27, 2.27–2.07, 
1.95–1.63, 1.63–1.48 (4m, CH2(4)(Gln), CH2(3)(Gln), CH2(3)(Iva), CH2(3)(Leu), 
CH(4)(Leu), CH(3)(Valol)); 1.40, 1.38, 1.31, 1.28 (4s, Me2C, MeC(2)(Iva)); 1.00–0.86 (m, 2 
Me(Leu), 2 Me(Valol)); 0.84, 0.75 (2t, J = 7.5, MeCH2(Iva)). 13C-NMR (CD3OD): 177.9, 
177.7, 177.6, 176.9, 176.8, 176.0, 174.4 (8s, 5 CO(amide)); 158.8 (s, CO(urethane)); 138.4, 
138.2 (2s, 1 arom. C); 129.5, 129.0, 128.5, 128.4 (4d, 5 arom. CH); 67.9, 67.8 (2t, PhCH2O); 
63.5 (t, CH2OH); 61.4, 61.0 (2s, C(2)(Iva)); 58.5, 58.4 (2d, C(2)(Gln)); 57.8 (s, Me2C); 56.3, 
55.9, 55.6 (3d, C(2)(Leu), C(2)(Valol)); 41.5, 41.3 (2t, C(3)(Leu)); 33.6, 33.5 (2t, C(4)(Gln)); 
32.7 (t, C(3)(Gln)); 30.0 (d, C(3)(Valol)); 28.4 (2t, C(3)(Iva)); 25.8 (d, C(4)(Leu)); 24.6, 24.5, 
23.3, 23.2, 22.3, 22.1, 21.7 (7q, Me2C, 2 Me(Leu), MeCH2(Iva)); 20.1, 19.4, 19.3 (3q, 2 Me 
(Valol)); 8.7, 8.0 (2q, C(4)(Iva)). ESI-MS: 701 (65, [M+K]+), 685 (100, [M+Na]+), 663 (29, 
[M+1]+).  
The coupling of 27 and 28 with DCC/HOBt according to GP D gave the same product, 
after PLC (SiO2, CH2Cl2/MeOH 95:5) in 29% yield. 
4.8. H-Leu-Aib-D,L-Iva-Gln-Valol (13). According to GP C, a mixture of Z-Leu-Aib-
D,L-Iva-Gln-Valol (500 mg, 0.75 mmol) and Pd/C (76 mg) in MeOH (10 ml) was treated with 
H2 for 47 h: 394 mg (99%) of 13. Colorless foam. M.p. 88.5–89.5°. 1H-NMR (CD3OD, 
mixture of epimers): 4.20–4.08 (m, CH(2)(Gln)); 3.73–3.57 (m, CH2(1)(Valol), 
CH(2)(Valol)); 2.81 (s, CH(2)(Leu)); 2.45–2.05, 2.00–1.65, 1.50–1.22 (3m, CH2(4)(Gln), 
CH2(3)(Gln), CH2(3)(Iva), CH2(3)(Leu), CH(4)(Leu), CH(3)(Valol), Me2C, MeC(2)(Iva)); 
1.00–0.70 (m, 2 Me(Leu), 2 Me(Valol), MeCH2(Iva)). ESI-MS: 595 (61), 567 (52, [M+K]+), 
551 (97, [M+Na]+), 529 (100, [M+1]+).  
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5. Coupling of the Segments 10, 19, and 13. 5.1. Z-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-
Aib-D,L-Iva-Gln-Valol (29). According to GP D, to a soln. of 19 (202 mg, 0.24 mmol) in 
DMF (2 ml) were added DCC (50 mg, 0.24 mmol), HOBt (37 mg, 0.27 mmol), CSA (8 mg), 
and 13 (154 mg, 0.29 mmol), and the mixture was stirred for 24 h: 125 mg (39%) of 29. 
Colorless crystals. M.p. 178.6–179.8° (AcOEt/Et2O/hexane). 1H-NMR (CD3OD, mixture of 
epimers): 8.04–7.52 (m, 5 NH); 7.47–7.16 (m, 5 arom. H, 1 NH); 5.18, 5.08 (AB, J = 12.5, 
PhCH2O); 4.47–4.29 (m, 2 H); 4.22–4.02 (m, 3 H); 3.95 (t-like, J = 6.8, 1 H); 3.88–3.76 (m, 1 
H); 3.76–3.53 (m, 4 H); 2.62–2.48 (m, 1 H); 2.43–1.22 (m, 56 H); 1.06–0.72 (m, 2 Me(Leu), 2 
Me(Valol), MeCH2(Iva)). ESI-MS: 1408 (23, [M+K]+), 1393 (100, [M+Na+1]+), 716 (56, 
[M+K+1]2+), 708 (100, [M+2 Na]2+).  
5.2. H-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-Aib-D,L-Iva-Gln-Valol. According to GP C, to 
a soln. of 29 (95 mg, 0.07 mmol) in MeOH (2 ml) was added Pd/C (21 mg), and the mixture 
was stirred under an H2 atmosphere for 48.5 h: 85 mg (quant.) of H-Gln-(Aib)3-Ala-Ala-Aib-
Pro-Leu-Aib-D,L-Iva-Gln-Valol. Colorless foam. 1H-NMR (CD3OD, mixture of epimers): 
7.32–7.18 (m, 2 NH); 4.50–4.32 (m, 2 H); 4.25–4.02 (m, 3 H); 3.87–3.77 (m, 1 H); 3.73–3.53 
(m, 3 H); 3.53–3.38 (m, 1 H); 3.38–3.20 (m, 1 H); 2.65–2.45, 2.45–2.08, 2.08–1.25 (3m, 54 
H); 1.25–1.03 (m, 3 H); 1.03–0.70 (m, 2 Me(Leu), 2 Me(Valol), MeCH2(Iva)). ESI-MS: 1236 
(34, [M+1]+), 630 (100, [M+Na+1]2+). 
5.3. Z-Aib-Gly-Aib-Leu-Aib-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-Aib-D,L-Iva-Gln-Valol 
(9). To a stirred soln. of 10 (28 mg, 0.05 mmol) in DMF (1.5 ml) at 0° was added DIEA (14 
mg, 0.11 mmol).  After 7 min, TBTU (17 mg, 0.05 mmol), HOBt (9 mg, 0.07 mmol), and, 
after another 5 min, H-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-Aib-D,L-Iva-Gln-Valol (69 mg, 0.06 
mmol), were added and the mixture was stirred for 25.5 h. After filtration through a Celite 
pad, DMF was evaporated, the residue was dissolved in AcOEt, washed with 2N HCl (2x) and 
1N NaOH, and dried (Na2SO4). CC (SiO2, AcOEt) and crystallization from 
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CH2Cl2/Et2O/hexane gave 32 mg (37%) of 9. Colorless crystals. ESI-MS: 1848 (29), 1834 
(30, [M+K+1]+), 1818 (100, [M+Na+1]+), 1710 (31).  
5.4. Z-Aib-Gly-Aib-Leu-Aib-Gln(Trt)-(Aib)3-Ala-Ala-Aib-Pro-OtBu (30). According to 
GP D, to a soln. of 10 (217 mg, 0.38 mmol) in DMF (4 ml) was added DIEA (98 mg, 0.76 
mmol). After stirring for 5 min, TBTU (121 mg, 0.38 mmol), HOBt (56 mg, 0.41 mmol), and, 
after another 9 min, 25 (408 m, 0.40 mmol) were added. The mixture was stirred for 16.5 h. 
Workup by CC and PLC (SiO2, CH2Cl2/MeOH) gave 304 mg (51%) of 30. Colorless foam. 
M.p. 168.8–169.7°. 1H-NMR (CD3OD): 8.33, 8.06 (2s, 2 NH); 8.02 (d, J = 5.2,  NH); 7.95, 
7.93, 7.91, 7.82 (4s, 4 NH); 7.69 (d, J = 5.6, NH); 7.50–7.00 (m, 20 arom. H); 5.17, 5.12 (AB, 
J = 12.8, PhCH2O); 4.38–4.25 (m, CH(2)(Ala), CH(2)(Pro)); 4.15–3.94 (m, CH(2)(Leu), 
CH(2)(Gln), CH(2)(Ala)); 3.82–3.62 (m, CH2(5)(Pro), CH2(Gly)); 2.65–2.53, 2.46–2.35 (m, 
CH2(4)(Gln)); 2.20–1.20 (m, 66 H); 0.94, 0.87 (2d, J = 6.5, 2 Me(Leu)). ESI-MS: 1644 (9, 
[M+K+Na]+), 1622 (15, [M+K+1]+), 1606 (100, [M+Na+1]+).  
5.5.  Z-Aib-Gly-Aib-Leu-Aib-Gln-(Aib)3-Ala-Ala-Aib-Pro-OH (31). According to GP 
E, a soln. of 30 (68 mg, 0.04 mmol) in TFA (1 ml) was stirred for 2.75 h: 55 mg (quant.) of 
31. Colorless crystals. M.p. 161.6–162.3° (CH2Cl2/Et2O/hexane). 1H-NMR (CD3OD): 8.77, 
8.02, 7.96, 7.94, 7.91, 7.81, 7.77, 7.61 (8s, 9 NH); 7.44–7.12 (m, 5 arom. H, 3 NH); 5.17, 5.12 
(AB, J = 12.7, PhCH2O); 4.44 (dd, J = 9.0, 4.1, CH(2)(Pro)); 4.38–4.25, 4.15–3.90 (2m, 
CH(2)(Leu), CH(2)(Gln), 2 CH(2)(Ala), CH2(Gly)); 3.80–3.62 (m, CH2(5)(Pro)); 2.50–2.35, 
2.35–2.22, 2.22–1.82, 1.82–1.34 (4m, 59 H); 0.94, 0.88 (2d, J = 5.8, 2 Me(Leu)). ESI-MS: 
1323 (32, [M+K]+), 1307 (100, [M+Na]+), 1211 (11).  
6. X-Ray Crystal-Structure Determination of 10 and 21 (see Table 5 and Figs. 1 and 
2)12). The measurements were made using graphite-monochromated MoKα radiation 
                                                          
12) CCDC-627754 & 627755 contain the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
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(λ  0.71073 Å) on a Nicolet-R3 diffractometer (21) or on a Rigaku AFC5R diffractometer 
fitted to a 12-kW rotating-anode generator (10).  The intensities were corrected for Lorentz 
and polarization effects, but not for absorption.  Equivalent reflections, other than Friedel 
pairs, were merged.  The data collection and refinement parameters are given in Table 5, and 
views of the molecules are shown in Figs. 1 and 2.  Each structure was solved by direct 
methods using SHELXS86 [54], which revealed the positions of all non-H-atoms.  The non-
H-atoms were refined anisotropically.  The amide and hydroxy H-atoms were placed in the 
positions indicated by difference electron density maps and their positions were allowed to 
refine together with individual isotropic displacement parameters.  All remaining H-atoms 
were placed in geometrically calculated positions and refined by using a riding model where 
each H-atom was assigned a fixed isotropic displacement parameter with a value equal to 
1.2Ueq of its parent C-atom (1.5Ueq for the methyl groups).  The refinement of each structure 
was carried out on F2 by using full-matrix least-squares procedures, which minimised the 
function Σw(Fo2 – Fc2)2.  A correction for secondary extinction was applied in the case of 21.  
For 10, two reflections, whose intensities were considered to be extreme outliers, were 
omitted from the final refinement.  Neutral atom scattering factors for non-H-atoms were 
taken from [55], and the scattering factors for H-atoms were taken from [56].  Anomalous 
dispersion effects were included in Fc [57]; the values for ƒ’ and ƒ” were those of [58].  The 
values of the mass attenuation coefficients are those of [59].  The SHELXL97 program was 
used for all calculations [60]. 
Table 4 
 
                                                                                                                                                                                     
via www.ccdc.cam.ac.uk/data_request/cif. 
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Legends 
 
Fig. 1. ORTEP-Plot [37] of the molecular structure of 10 (arbitrary numbering of 
atoms, 50% probability ellipsoids, H-atoms bonded to C-atoms have been omitted for clarity) 
 
Fig. 2. ORTEP-Plot [37] of the molecular structure of 21 (arbitrary numbering of 
atoms, 30% probability ellipsoids, H-atoms bonded to C-atoms have been omitted for clarity) 
 
Fig. 3. Mass-Spectra of the Octapeptide 19; a) ESI-MS and b) FAB-MS 
 
Fig. 4. Mass-Spectra of the Tridecapeptides 30 and 31; a) ESI-MS of 30, b) ESI-MS of 
31, and c) FAB-MS of 31 
 
Table 1. Sequences of Trichotoxins A-50 [15] 
 
Table 2. Torsion Angles and H-Bonding Parameters in the Crystal-Structure of 10  
 
Table 3. Torsion Angles and H-Bonding Parameters in the Crystal-Structure of 21  
 
Table 4. Yields of the Coupling of Azirine 2a and the Hydrolysis of the Terminal 
Amide Group of Z-Gln(X)-(Aib)n-N(Me)Ph Derivatives 
 
Table 5.  Crystallographic Data for Compounds 10 and 21  
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Table 1. Sequences of Trichotoxins A-50 [15] 
 
Ac-Aib-Gly-Aib-Leu-Aib-Gln-Aib-Aib-Aib-Ala-Ala-Aib-Pro-Leu-Aib-Aib-Gln-Valol   (E)
Ac-Aib-Gly-Aib-Leu-Aib-Gln-Aib-Aib-Ala-Ala-Ala-Aib-Pro-Leu-Aib-Iva-Gln-Valol   (F)
Ac-Aib-Gly-Aib-Leu-Aib-Gln-Aib-Aib-Aib-Ala-Ala-Aib-Pro-Leu-Aib-Iva-Gln-Valol   (G)
Ac-Aib-Ala-Aib-Leu-Aib-Gln-Aib-Aib-Aib-Ala-Ala-Aib-Pro-Leu-Aib-Iva-Gln-Valol   (H)
Ac-Aib-Gly-Aib-Leu-Aib-Gln-Aib-Aib-Aib-Ala-Aib-Aib-Pro-Leu-Aib-Iva-Gln-Valol   (I)
Ac-Aib-Ala-Aib-Leu-Aib-Gln-Aib-Aib-Aib-Ala-Aib-Aib-Pro-Leu-Aib-Iva-Gln-Valol   (J)
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Table 2. Torsion Angles and H-Bonding Parameters in the Crystal-Structure of 10  
Amino Acid φ [°] ψ [°] ω [°]  
Aib(1) –56.5(3) –51.4(3) –174.0(2) 
Gly(2) –69.7(3) –50.4(3) –175.2(2) 
Aib(3) –54.9(3) –41.8(3) –171.4(2) 
Leu(4) –103.3(3) 16.6(3) 176.2(2) 
Aib(5) 52.9(3) 47.4(3) - 
 
D–H…A D…A [Å] D–H…A [°]  
N(4)–H…O(2) 3.049(3) 155(3) 
N(5)–H…O(4) 3.130(3) 168(3) 
O(8)–H…O(3) 2.667(3) 167(4) 
N(1)–H…O(5')a) 2.992(3) 142(3) 
N(2)–H…O(6") 2.905(3) 134(3) 
N(3)–H…O(7") 2.923(3) 172(3) 
 
a) Primed atoms refer to the molecule in the following symmetry related positions: 
' 1 + x, y, z;  " 1 – x, –1/2 + y,  1 – z 
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Table 3. Torsion Angles and H-Bonding Parameters in the Crystal-Structure of 21  
Amino Acid φ [°] ψ [°] ω [°] 
Ala(1) –81.9(7) –11.4(7) 174.4(5) 
Ala(2) –133.6(5) 141.3(5) 169.9(5) 
Aib(3) 52.8(7) 43.9(6) 171.5(4) 
Pro(4) –64.8(6) –32.5(6) –171.5(5) 
D–H…A D…A [Å] D–H…A [°] 
N(1)–H…O(3')a) 2.893(7) 178(4) 
N(3)–H…O(5") 2.835(6) 178(6) 
 
a) Primed atoms refer to the molecule in the following symmetry related positions: 
' 2 – x, 1/2 + y, 1 – z;  " 2 – x, –1/2 + y,  2 – z 
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Table 4.  Yields of the Coupling of Z-Gln(X)-OH with Azirine 2a and the Hydrolysis of the 
Terminal Amide Group of Z-Gln(X)-(Aib)n Derivatives 
 
Peptide Yield [%] 
Protecting Group X Trt DMB Dod 
Z-Gln(X)-Aib-N(Me)Pha) 89 83 94 
Z-Gln(X)-Aib-OHb) 98 98 97 
Z-Gln(X)-(Aib)2-N(Me)Pha) 87 88 97 
Z-Gln(X)-(Aib)2-OHb) quant. 99 97 
Z-Gln(X)-(Aib)3-N(Me)Pha) 89 95 85 
Z-Gln(X)-(Aib)3-OHb) 92 (11a) 95 (11b) quant. (11c) 
Total yield of 11c) 62.1 63.9 72.9 
 
a) Coupling of Z-Gln(X)-OH (23a–23c) with 2a in CH2Cl2 at r.t. 
b) Hydrolysis in 3N HCl (THF/H2O 1:1) at r.t. 
c) Total yield with respect to 23. 
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Table 5.  Crystallographic Data for Compounds 10 and 21  
__________________________________________________________________________________ 
 
 10 21 
__________________________________________________________________________________ 
 
Crystallized from CH2Cl2/Et2O/hexane MeOH/H2O/CH2Cl2 
Empirical formula C28H43N5O8 C27H40N4O7 
Formula weight 577.67 532.63 
Crystal color, habit colorless, prism colorless, prism 
Temperature [K] 173(1) 295(1) 
Crystal system monoclinic monoclinic 
Space group P21 P21 
Z 2 2 
Reflections for cell determination 25 25 
2θ range for cell determination [°] 38–40 24–28 
Unit cell parameters a [Å] 9.841(4) 11.475(15) 
 b [Å] 16.668(4) 10.381(13) 
 c [Å] 10.422(6) 12.930(15) 
 β [°] 113.44(4) 101.07(10) 
 V [Å3] 1568(1) 1512(3) 
Dx [g cm-3] 1.223 1.171 
µ(MoKα) [mm-1] 0.090  0.085 
Scan type ω/2θ ω 
2θ(max) [°] 60 46 
Total reflections measured 4969 2952 
Symmetry independent reflections 4717 2522 
Reflections with I > 2σ(I)  3588  1556 
Reflections used in refinement 4715 2522 
Parameters refined; restraints 402; 1 363; 1 
Final R(F)  [I > 2σ (I) reflections] 0.0441  0.0472 
 wR(F2) (all data) 0.1092  0.0780 
Weighting parameters (a; b)a) 0.0384; 0.4557 0.0342; 0 
Goodness of fit 1.025 0.986 
Final ∆max/σ 0.001 0.001 
∆ρ (max; min) [e Å–3] 0.29; –0.21 0.11; –0.11 
 
a) w–1 = σ 2(Fo2) + (aP)2 + bP where P = (Fo2 + 2Fc2)/3 
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Scheme 1 
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Scheme 2 
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Scheme 3 
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Scheme 4 
 
 
 
+Z-Gly-OH 2a Z-Gly-Aib-N(Me)Ph
b)
96%
Z-Gly-Aib-OH
a)
93%
14 15
+Z-Leu-OH 2a Z-Leu-Aib-N(Me)Ph
d)
94%
H-Leu-Aib-N(Me)Ph
c)
99%
16 17
H-Gly-Aib-Leu-Aib-N(Me)Ph
f), b)
76%
Z-Aib-Gly-Aib-Leu-Aib-OH
e), d)
79%
18 10
15  +  17
a) THF, r.t.; b) 3N HCl, H2O/THF, r.t.; c) Et2O, r.t.; d) H2, Pd/C, MeOH, r.t.;
e) DCC, HOBt, ZnCl2, DMF, 0°      r.t.; f) Z-Aib-OH, DCC, HOBt, CSA, 0°      r.t.
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Scheme 5 
 
 
 
+Z-Ala-Ala-OH 2a Z-Ala-Ala-Aib-OH
c)
89%
X-Ala-Ala-Aib-Pro-OtBu
a), b)
92%
20 21  X = Z
12  X = H
a) THF, r.t.; b) 3N HCl, H2O/THF, r.t.; c) H-Pro-OtBu, DCC, HOBt, CSA, DMF, 0°         r.t.;
d) H2, Pd/C, MeOH
d) 98%
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Scheme 6 
 
 
 
Z-Gln(Trt)-(Aib)3-OH   +   H-Ala-Ala-Aib-Pro-OtBu
a)
97%
Z-Gln(Trt)-(Aib)3-Ala-Ala-Aib-Pro-OtBu
c)
quant.
11a 12
24
Z-Gln-(Aib)3-Ala-Ala-Aib-Pro-OH
19b)   97%
H-Gln(Trt)-(Aib)3-Ala-Ala-Aib-Pro-OtBu
25
a) DCC, HOBt, CSA, DMF, 0°    r.t.; b) H2, Pd/C, MeOH, r.t.
c) CF3COOH, 0°
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Scheme 7 
 
 
 
Z-Leu-OH   +   2a
a), b)
91%
a) Et2O, 0°    r.t.; b) 3N HCl, H2O/THF, r.t.; c) CH2Cl2, 0°    r.t.; d) ClCO2Et, NMM, -10°    r.t.;
e) H2, Pd/C, MeOH, r.t.; f) TBTU, HOBt, DIEA, DMF, 0°    r.t.
Z-Leu-Aib-OH
c), b)
55%
Z-Leu-Aib-D,L-Iva-OH
27
Z-Gln-OH   +   H-Valol
d), e)
86%
H-Gln-Valol
28
27   +   28
f), e)
77%
H-Leu-Aib-D,L-Iva-Gln-Valol
13
26
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Scheme 8 
 
 
 
Z-Gln-(Aib)3-Ala-Ala-Aib-Pro-OH    +    H-Leu-Aib-D,L-Iva-Gln-Valol
19
a)   39%
9
a) DCC, HOBt, CSA, DMF, 0°    r.t.; b) H2, Pd/C, MeOH, r.t.; c) 10, DIEA, TBTU, HOBt, 0°    r.t.
13
Z-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-Aib-D,L-Iva-Gln-Valol
29
b),c)   37%
Z-Aib-Gly-Aib-Leu-Aib-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-Aib-D,L-Iva-Gln-Valol
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Graphical Abstract 
 
 Z-Aib-Gly-Aib-Leu-Aib-Gln-(Aib)3-Ala-Ala-Aib-Pro-Leu-Aib-D,L-Iva-Gln-Valol
N
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N
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